 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE increase or decrease the risk of aplastic anemia?[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ALENDRONATE increase the risk of aplastic anemia?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ALENDRONATE increase the risk of aplastic anemia?[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE increase the risk of aplastic anemia?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE increase the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ALENDRONATE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: ALENDRONATE: adverse_reactions: [0m[1;31m1[0m[31m [0m[1;31m1.8[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.2[0m[31m Diarrhea [0m[1;31m3.1[0m[31m [0m[1;31m1.8[0m[31m [0m[1;31m0.6[0m[31m [0m[1;31m0.3[0m[31m Flatulence [0m[1;31m2.6[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m0.2[0m[31m [0m[1;31m0.3[0m[31m Acid regurgitation [0m[1;31m2.0[0m[31m [0m[1;31m4.3[0m[31m [0m[1;31m1.1[0m[31m [0m[1;31m0.9[0m[31m Esophageal ulcer [0m[1;31m1.5[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.1[0m[31m [0m[1;31m0.1[0m[31m Vomiting [0m[1;31m1.0[0m[31m [0m[1;31m1.5[0m[31m [0m[1;31m0.2[0m[31m [0m[1;31m0.3[0m[31m [0m
[31mDysphagia [0m[1;31m1.0[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.1[0m[31m [0m[1;31m0.1[0m[31m Abdominal distention [0m[1;31m1.0[0m[31m [0m[1;31m0.8[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.0[0m[31m Gastritis [0m[1;31m0.5[0m[31m [0m[1;31m1.3[0m[31m [0m[1;31m0.6[0m[31m [0m[1;31m0.7[0m[31m Musculoskeletal Musculoskeletal [0m[1;31m([0m[31mbone, muscle or joint[0m[1;31m)[0m[31m pain [0m[1;31m4.1[0m[31m [0m[1;31m2.5[0m[31m [0m[1;31m0.4[0m[31m [0m[1;31m0[0m[31m. ALENDRONATE: adverse_reactions: [0m[1;31m3[0m[31m [0m
[31mMuscle cramp [0m[1;31m0.0[0m[31m [0m[1;31m1.0[0m[31m [0m[1;31m0.2[0m[31m [0m[1;31m0.1[0m[31m Nervous system/psychiatric Headache [0m[1;31m2.6[0m[31m [0m[1;31m1.5[0m[31m [0m[1;31m0.2[0m[31m [0m[1;31m0.2[0m[31m Dizziness [0m[1;31m0.0[0m[31m [0m[1;31m1.0[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.1[0m[31m Special senses Taste perversion [0m[1;31m0.5[0m[31m [0m[1;31m1.0[0m[31m [0m[1;31m0.1[0m[31m [0m[1;31m0.0[0m[31m Rarely, rash and erythema have occurred. [0m
[31mGastrointestinal Adverse Reactions: One patient treated with alendronate sodium [0m[1;31m([0m[1;31m10[0m[31m mg/day[0m[1;31m)[0m[31m, who had a history of peptic ulcer disease and gastrectomy and who was taking concomitant aspirin developed [0m
[31man anastomotic ulcer with mild hemorrhage, which was considered drug related. Aspirin and alendronate sodium were discontinued and the patient recovered. ALENDRONATE: adverse_reactions: In the Study [0m[1;31m1[0m
[31mand Study [0m[1;31m2[0m[31m populations, [0m[1;31m49[0m[31m-[0m[1;31m54[0m[31m% had a history of gastrointestinal disorders at baseline and [0m[1;31m54[0m[31m-[0m[1;31m89[0m[31m% used nonsteroidal anti-inflammatory drugs or aspirin at some time during the studies [0m[1;31m[[0m[31m see Warnings [0m
[31mand Precautions [0m[1;31m([0m[1;31m5.1[0m[1;31m)[0m[31m [0m[1;31m][0m[31m. Laboratory Test Findings: In double-blind, multicenter, controlled studies, asymptomatic, mild, and transient decreases in serum calcium and phosphate were observed in [0m
[31mapproximately [0m[1;31m18[0m[31m% and [0m[1;31m10[0m[31m%, respectively, of patients taking alendronate versus approximately [0m[1;31m12[0m[31m% and [0m[1;31m3[0m[31m% of those taking placebo. However, the incidences of decreases in serum calcium to less than [0m[1;31m8.0[0m[31m [0m
[31mmg/dL [0m[1;31m([0m[1;31m2.0[0m[31m mM[0m[1;31m)[0m[31m and serum phosphate to less than or equal to [0m[1;31m2.0[0m[31m mg/dL [0m[1;31m([0m[1;31m0.65[0m[31m mM[0m[1;31m)[0m[31m were similar in both treatment groups. ALENDRONATE: adverse_reactions: Weekly Dosing The safety of alendronate sodium [0m[1;31m70[0m
[31mmg once weekly for the treatment of postmenopausal osteoporosis was assessed in a one-year, double-blind, multicenter study comparing alendronate [0m[1;31m70[0m[31m mg once weekly and alendronate [0m[1;31m10[0m[31m mg daily. The [0m
[31moverall safety and tolerability profiles of once weekly alendronate [0m[1;31m70[0m[31m mg and alendronate [0m[1;31m10[0m[31m mg daily were similar. The adverse reactions considered by the investigators as possibly, probably, or [0m
[31mdefinitely drug related in greater than or equal to [0m[1;31m1[0m[31m% of patients in either treatment group are presented in Table [0m[1;31m2[0m[31m. ALENDRONATE: adverse_reactions: Table [0m[1;31m2[0m[31m Osteoporosis Treatment Studies in [0m
[31mPostmenopausal Women Adverse Reactions Considered Possibly, Probably, or Definitely Drug Related by the Investigators and Reported in Greater Than or Equal to [0m[1;31m1[0m[31m% of Patients Once Weekly Alendronate [0m
[31mSodium [0m[1;31m70[0m[31m mg % [0m[1;31m([0m[31mN = [0m[1;31m519[0m[1;31m)[0m[31m Once Daily Alendronate Sodium [0m[1;31m10[0m[31m mg % [0m[1;31m([0m[31mN = [0m[1;31m370[0m[1;31m)[0m[31m Gastrointestinal Abdominal pain [0m[1;31m3.7[0m[31m [0m[1;31m3.0[0m[31m Dyspepsia [0m[1;31m2.7[0m[31m [0m[1;31m2.2[0m[31m Acid regurgitation [0m[1;31m1.9[0m[31m [0m[1;31m2.4[0m[31m Nausea [0m[1;31m1.9[0m[31m [0m[1;31m2.4[0m[31m Abdominal distention [0m[1;31m1.0[0m[31m [0m
[1;31m1.4[0m[31m Constipation [0m[1;31m0.8[0m[31m [0m[1;31m1.6[0m[31m Flatulence [0m[1;31m0.4[0m[31m [0m[1;31m1.6[0m[31m Gastritis [0m[1;31m0.2[0m[31m [0m[1;31m1.1[0m[31m Gastric ulcer [0m[1;31m0.0[0m[31m [0m[1;31m1[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: adverse_reactions: [0m[1;31m0[0m[31m Abdominal pain [0m[1;31m2.1[0m[31m [0m[1;31m1.1[0m[31m [0m[1;31m0.9[0m[31m [0m[1;31m3.4[0m[31m Nausea [0m[1;31m2.1[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m6.2[0m[31m Post-Marketing Experience The following adverse reactions have been identified during post-approval[0m
[31muse of alendronate sodium. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal [0m
[31mrelationship to drug exposure. Body as a Whole : hypersensitivity reactions including urticaria and angioedema. Transient symptoms of myalgia, malaise, asthenia and fever have been reported with [0m
[31malendronate, typically in association with initiation of treatment. Symptomatic hypocalcemia has occurred, generally in association with predisposing conditions. Peripheral edema. ALENDRONATE: [0m
[31madverse_reactions: Gastrointestinal : esophagitis, esophageal erosions, esophageal ulcers, esophageal stricture or perforation, and oropharyngeal ulceration. Gastric or duodenal ulcers, some severe [0m
[31mand with complications have also been reported [0m[31m . Dental : Localized osteonecrosis of the jaw, generally associated with tooth extraction and/or local infection with delayed healing, has been reported[0m
[31m. Musculoskeletal : bone, joint, and/or muscle pain, occasionally severe and incapacitating [0m[31m ; joint swelling; low-energy femoral shaft and subtrochanteric fractures [0m[31m . Nervous system : dizziness and [0m
[31mvertigo. ALENDRONATE: adverse_reactions: Pulmonary: acute asthma exacerbations Skin : rash [0m[1;31m([0m[31moccasionally with photosensitivity[0m[1;31m)[0m[31m, pruritus, alopecia, severe skin reactions, including Stevens-Johnson [0m
[31msyndrome and toxic epidermal necrolysis. Special Senses : uveitis, scleritis or episcleritis. Cholesteatoma of the external auditory canal [0m[1;31m([0m[31mfocal osteonecrosis[0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: adverse_reactions_table: >[0m[1;31m10[0m[31m mg % [0m[1;31m([0m[31mN = [0m[1;31m146[0m[1;31m)[0m[1;31m<[0m[31m/[0m[31mth[0m[31m><th>Placebo % [0m[1;31m([0m[31mN = [0m[1;31m95[0m[1;31m)[0m[31m<[0m[31m/[0m[31mth[0m[31m><th>[0m[1;31m70[0m[31m mg % [0m[1;31m([0m[31mN = [0m[1;31m109[0m[1;31m)[0m[31m<[0m[31m/[0m[31mth[0m[31m><th>Placebo % [0m[1;31m([0m[31mN = [0m[1;31m58[0m[1;31m)[0m[31m<[0m[31m/[0m[31mth[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mthead[0m[31m><tbody><tr><td [0m
[31mcolspan[0m[31m=[0m[31m"5"[0m[31m>Gastrointestinal<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Acid regurgitation<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m4.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m3.2[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> [0m
[31mFlatulence<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m4.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Gastroesophageal reflux disease<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.7[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m3.2[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2[0m[31m. ALENDRONATE: adverse_reactions_table: [0m
[1;31m8[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Dyspepsia<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m3.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.8[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.7[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Diarrhea<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.8[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Abdominal [0m
[31mpain<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.9[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m3.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Nausea<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0[0m[31m. ALENDRONATE: adverse_reactions_table: [0m[1;31m0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[31m>         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: openfda: spl_set_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: contraindications: [0m[1;31m4[0m[31m CONTRAINDICATIONS BINOSTO is contraindicated in patients with the following conditions: Abnormalities of the esophagus which delay esophageal emptying such [0m
[31mas stricture or achalasia [0m[31m Inability to stand or sit upright for at least [0m[1;31m30[0m[31m minutes [0m[31m Do not administer BINOSTO to patients at increased risk of aspiration Hypocalcemia [0m[31m Hypersensitivity to any [0m
[31mcomponent of this product. Hypersensitivity reactions including urticaria and angioedema have been reported [0m[31m . Abnormalities of the esophagus which delay emptying such as stricture or achalasia [0m[1;31m([0m[31m [0m[1;31m4[0m[31m , [0m
[1;31m5[0m[31m. ALENDRONATE: contraindications: [0m[1;31m1[0m[31m [0m[1;31m)[0m[31m Inability to stand/sit upright for at least [0m[1;31m30[0m[31m minutes [0m[1;31m([0m[31m [0m[1;31m4[0m[31m , [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[31m Increased risk of aspiration. [0m[1;31m([0m[31m [0m[1;31m4[0m[31m [0m[1;31m)[0m[31m Hypocalcemia [0m[1;31m([0m[31m [0m[1;31m4[0m[31m , [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m Hypersensitivity to any component[0m
[31mof this product [0m[1;31m([0m[31m [0m[1;31m4[0m[31m , [0m[1;31m6[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: animal_pharmacology_and_or_toxicology: [0m[1;31m13.2[0m[31m Animal Toxicology and/or Pharmacology The relative inhibitory activities on bone resorption and mineralization of alendronate and [0m
[31metidronate were compared in the Schenk assay, which is based on histological examination of the epiphyses of growing rats. In this assay, the lowest dose of alendronate that interfered with bone [0m
[31mmineralization [0m[1;31m([0m[31mleading to osteomalacia[0m[1;31m)[0m[31m was [0m[1;31m6000[0m[31m-fold the antiresorptive dose. The corresponding ratio for etidronate was one to one. These data suggest that alendronate administered in therapeutic [0m
[31mdoses is highly unlikely to induce osteomalacia.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: nonclinical_toxicology: [0m[1;31m13[0m[31m NONCLINICAL TOXICOLOGY [0m[1;31m13.1[0m[31m Carcinogenesis, Mutagenesis, Impairment of Fertility Harderian gland [0m[1;31m([0m[31ma retro-orbital gland not present in humans[0m[1;31m)[0m[31m adenomas[0m
[31mwere increased in high-dose female mice [0m[1;31m([0m[31mp[0m[31m=[0m[1;31m0[0m[1;31m.003[0m[1;31m)[0m[31m in a [0m[1;31m92[0m[31m-week oral carcinogenicity study at doses of alendronate of [0m[1;31m1[0m[31m, [0m[1;31m3[0m[31m, and [0m[1;31m10[0m[31m mg/kg/day [0m[1;31m([0m[31mmales[0m[1;31m)[0m[31m or [0m[1;31m1[0m[31m, [0m[1;31m2[0m[31m, and [0m[1;31m5[0m[31m mg/kg/day [0m[1;31m([0m[31mfemales[0m[1;31m)[0m[31m. These doses are [0m
[31mequivalent to [0m[1;31m0.12[0m[31m to [0m[1;31m1.2[0m[31m times a maximum recommended daily dose of [0m[1;31m40[0m[31m mg, based on surface area, mg/m [0m[1;31m2[0m[31m . The relevance of this finding to humans is unknown. Parafollicular cell [0m[1;31m([0m[31mthyroid[0m[1;31m)[0m[31m adenomas [0m
[31mwere increased in high-dose male rats [0m[1;31m([0m[31mp[0m[31m=[0m[1;31m0[0m[31m. ALENDRONATE: nonclinical_toxicology: [0m[1;31m003[0m[1;31m)[0m[31m in a [0m[1;31m2[0m[31m-year oral carcinogenicity study at doses of [0m[1;31m1[0m[31m and [0m[1;31m3.75[0m[31m mg/kg body weight. These doses are equivalent to [0m
[1;31m0.26[0m[31m and [0m[1;31m1[0m[31m times a [0m[1;31m40[0m[31m mg human daily dose based on surface area, mg/m [0m[1;31m2[0m[31m . The relevance of this finding to humans is unknown. Alendronate sodium was not genotoxic in the in vitro microbial mutagenesis[0m
[31massay with and without metabolic activation, in an in vitro mammalian cell mutagenesis assay, in an in vitro alkaline elution assay in rat hepatocytes, and in an in vivo chromosomal aberration assay [0m
[31min mice. In an in vitro chromosomal aberration assay in Chinese hamster ovary cells, however, alendronate gave equivocal results. Alendronate sodium had no effect on fertility [0m[1;31m([0m[31mmale or female[0m[1;31m)[0m[31m in rats[0m
[31mat oral doses up to [0m[1;31m5[0m[31m mg/kg/day [0m[1;31m([0m[1;31m1[0m[31m. ALENDRONATE: nonclinical_toxicology: [0m[1;31m3[0m[31m times a [0m[1;31m40[0m[31m mg human daily dose based on surface area, mg/m [0m[1;31m2[0m[31m [0m[1;31m)[0m[31m. [0m[1;31m13.2[0m[31m Animal Toxicology and/or Pharmacology The relative [0m
[31minhibitory activities on bone resorption and mineralization of alendronate and etidronate were compared in the Schenk assay, which is based on histological examination of the epiphyses of growing [0m
[31mrats. In this assay, the lowest dose of alendronate that interfered with bone mineralization [0m[1;31m([0m[31mleading to osteomalacia[0m[1;31m)[0m[31m was [0m[1;31m6000[0m[31m-fold the antiresorptive dose. The corresponding ratio for etidronate was[0m
[31mone to one. These data suggest that alendronate administered in therapeutic doses is highly unlikely to induce osteomalacia.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: clinical_pharmacology: [0m[1;31m12[0m[31m CLINICAL PHARMACOLOGY [0m[1;31m12.1[0m[31m Mechanism of Action Animal studies have indicated the following mode of action. At the cellular level, alendronate shows [0m
[31mpreferential localization to sites of bone resorption, specifically under osteoclasts. The osteoclasts adhere normally to the bone surface but lack the ruffled border that is indicative of active [0m
[31mresorption. Alendronate does not interfere with osteoclast recruitment or attachment, but it does inhibit osteoclast activity. Studies in mice on the localization of radioactive [0m[1;31m[[0m[31m [0m[1;31m3[0m[31m H[0m[1;31m][0m[31malendronate in [0m
[31mbone showed about [0m[1;31m10[0m[31m-fold higher uptake on osteoclast surfaces than on osteoblast surfaces. Bones examined [0m[1;31m6[0m[31m and [0m[1;31m49[0m[31m days after [0m[1;31m[[0m[31m [0m[1;31m3[0m[31m H[0m[1;31m][0m[31malendronate administration in rats and mice, respectively, showed [0m
[31mthat normal bone was formed on top of the alendronate, which was incorporated inside the matrix. ALENDRONATE: clinical_pharmacology: While incorporated in bone matrix, alendronate is not [0m
[31mpharmacologically active. Thus, alendronate must be continuously administered to suppress osteoclasts on newly formed resorption surfaces. Histomorphometry in baboons and rats showed that alendronate [0m
[31mtreatment reduces bone turnover [0m[1;31m([0m[31mi.e., the number of sites at which bone is remodeled[0m[1;31m)[0m[31m. In addition, bone formation exceeds bone resorption at these remodeling sites, leading to progressive gains in [0m
[31mbone mass. [0m[1;31m12.2[0m[31m Pharmacodynamics Alendronate is a bisphosphonate that binds to bone hydroxyapatite and specifically inhibits the activity of osteoclasts, the bone-resorbing cells. Alendronate reduces [0m
[31mbone resorption with no direct effect on bone formation, although the latter process is ultimately reduced because bone resorption and formation are coupled during bone turnover. ALENDRONATE: [0m
[31mclinical_pharmacology: Osteoporosis in Postmenopausal Women Osteoporosis is characterized by low bone mass that leads to an increased risk of fracture. The diagnosis can be confirmed by the finding of[0m
[31mlow bone mass, evidence of fracture on x-ray, a history of osteoporotic fracture, or height loss or kyphosis, indicative of vertebral [0m[1;31m([0m[31mspinal[0m[1;31m)[0m[31m fracture. Osteoporosis occurs in both males and females [0m
[31mbut is most common among women following the menopause, when bone turnover increases and the rate of bone resorption exceeds that of bone formation. These changes result in progressive bone loss and [0m
[31mlead to osteoporosis in a significant proportion of women over age [0m[1;31m50[0m[31m. Fractures, usually of the spine, hip, and wrist, are the common consequences. From age [0m[1;31m50[0m[31m to age [0m[1;31m90[0m[31m, the risk of hip fracture in [0m
[31mwhite women increases [0m[1;31m50[0m[31m-fold and the risk of vertebral fracture [0m[1;31m15[0m[31m- to [0m[1;31m30[0m[31m-fold. ALENDRONATE: clinical_pharmacology: It is estimated that approximately [0m[1;31m40[0m[31m% of [0m[1;31m50[0m[31m-year-old women will sustain one or [0m
[31mmore osteoporosis-related fractures of the spine, hip, or wrist during their remaining lifetimes. Hip fractures, in particular, are associated with substantial morbidity, disability, and mortality. [0m
[31mDaily oral doses of alendronate sodium [0m[1;31m([0m[1;31m5[0m[31m, [0m[1;31m20[0m[31m, and [0m[1;31m40[0m[31m mg for six weeks[0m[1;31m)[0m[31m in postmenopausal women produced biochemical changes indicative of dose-dependent inhibition of bone resorption, including [0m
[31mdecreases in urinary calcium and urinary markers of bone collagen degradation [0m[1;31m([0m[31msuch as deoxypyridinoline and cross-linked N-telopeptides of type I collagen[0m[1;31m)[0m[31m. These biochemical changes tended to return[0m
[31mtoward baseline values as early as [0m[1;31m3[0m[31m weeks following the discontinuation of therapy with alendronate and did not differ from placebo after [0m[1;31m7[0m[31m months. ALENDRONATE: clinical_pharmacology: Long-term [0m
[31mtreatment of osteoporosis with alendronate sodium [0m[1;31m10[0m[31m mg/day [0m[1;31m([0m[31mfor up to five years[0m[1;31m)[0m[31m reduced urinary excretion of markers of bone resorption, deoxypyridinoline and cross-linked N-telopeptides of type l [0m
[31mcollagen, by approximately [0m[1;31m50[0m[31m% and [0m[1;31m70[0m[31m%, respectively, to reach levels similar to those seen in healthy premenopausal women. Similar decreases were seen in patients in osteoporosis prevention studies [0m
[31mwho received alendronate sodium [0m[1;31m5[0m[31m mg/day. The decrease in the rate of bone resorption indicated by these markers was evident as early as [0m[1;31m1[0m[31m month and at [0m[1;31m3[0m[31m to [0m[1;31m6[0m[31m months reached a plateau that was [0m
[31mmaintained for the entire duration of treatment with alendronate sodium.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: indications_and_usage: [0m[1;31m1[0m[31m INDICATIONS AND USAGE BINOSTO is a bisphosphonate indicated for: Treatment of osteoporosis in postmenopausal women [0m[1;31m([0m[31m [0m[1;31m1.1[0m[31m [0m[1;31m)[0m[31m Treatment to increase bone [0m
[31mmass in men with osteoporosis [0m[1;31m([0m[31m [0m[1;31m1.2[0m[31m [0m[1;31m)[0m[31m Limitation of use: Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after [0m[1;31m3[0m[31m to [0m[1;31m5[0m[31m years of use[0m
[1;31m([0m[31m [0m[1;31m1.3[0m[31m [0m[1;31m)[0m[31m [0m[1;31m1.1[0m[31m Treatment of Osteoporosis in Postmenopausal Women BINOSTO effervescent tablet [0m[1;31m70[0m[31m mg is indicated for the treatment of osteoporosis in postmenopausal women. For the treatment of [0m
[31mosteoporosis, alendronate sodium increases bone mass and reduces the incidence of fractures, including those of the hip and spine [0m[1;31m([0m[31mvertebral compression fractures[0m[1;31m)[0m[31m. [0m[1;31m[[0m[31mSee Clinical Studies [0m[1;31m([0m[1;31m14.1[0m[1;31m)[0m[31m .[0m[1;31m][0m[31m [0m[1;31m1[0m[31m. [0m
[31mALENDRONATE: indications_and_usage: [0m[1;31m2[0m[31m Treatment to Increase Bone Mass in Men With Osteoporosis BINOSTO is indicated for treatment to increase bone mass in men with osteoporosis [0m[31m . [0m[1;31m1.3[0m[31m Important [0m
[31mLimitations of Use The optimal duration of use has not been determined. The safety and effectiveness of BINOSTO for the treatment of osteoporosis are based on clinical data of four years duration. All[0m
[31mpatients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after [0m[1;31m3[0m[31m [0m
[31mto [0m[1;31m5[0m[31m years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: warnings_and_cautions: There have been post-marketing reports of gastric and duodenal ulcers with oral bisphosphonate use, some severe and with complications, although no [0m
[31mincreased risk was observed in controlled clinical trials [0m[31m . [0m[1;31m5.2[0m[31m Mineral Metabolism Hypocalcemia must be corrected before initiating therapy with BINOSTO [0m[31m. Other disorders affecting mineral metabolism[0m
[1;31m([0m[31msuch as vitamin D deficiency[0m[1;31m)[0m[31m should also be effectively treated. In patients with these conditions, serum calcium and symptoms of hypocalcemia should be monitored during therapy with BINOSTO. [0m
[31mPresumably due to the effects of BINOSTO on increasing bone mineral, small, asymptomatic decreases in serum calcium and phosphate may occur. Patients should receive adequate calcium and vitamin D [0m
[31mintake. [0m[1;31m5[0m[31m. ALENDRONATE: warnings_and_cautions: [0m[1;31m3[0m[31m Musculoskeletal Pain In post-marketing experience, severe and occasionally incapacitating bone, joint, and/or muscle pain has been reported in patients[0m
[31mtaking bisphosphonates that are approved for the treatment of osteoporosis [0m[31m . This category of drugs includes BINOSTO. Most of the patients were postmenopausal women. The time to onset of symptoms [0m
[31mvaried from one day to several months after starting the drug. Discontinue use if severe symptoms develop. Most patients had relief of symptoms after stopping. A subset had recurrence of symptoms when[0m
[31mrechallenged with the same drug or another bisphosphonate. In placebo-controlled clinical studies of alendronate sodium, the percentages of patients with these symptoms were similar in the alendronate[0m
[31msodium and placebo groups. [0m[1;31m5[0m[31m. ALENDRONATE: warnings_and_cautions: [0m[1;31m4[0m[31m Osteonecrosis of the Jaw Osteonecrosis of the jaw [0m[1;31m([0m[31mONJ[0m[1;31m)[0m[31m, which can occur spontaneously, is generally associated with tooth [0m
[31mextraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates, including alendronate sodium. Known risk factors for osteonecrosis of the jaw include [0m
[31minvasive dental procedures [0m[1;31m([0m[31me.g., tooth extraction, dental implants, boney surgery[0m[1;31m)[0m[31m, diagnosis of cancer, concomitant therapies [0m[1;31m([0m[31me.g., chemotherapy, corticosteroids, angiogenesis inhibitors[0m[1;31m)[0m[31m, poor [0m
[31moral hygiene, and co-morbid disorders [0m[1;31m([0m[31me.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures[0m[1;31m)[0m[31m. The risk of ONJ may increase with duration of[0m
[31mexposure to bisphosphonates. For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ. ALENDRONATE: warnings_and_cautions: Clinical [0m
[31mjudgment of the treating physician and/or oral surgeon should guide the management plan of each patient based on individual benefit/risk assessment. Patients who develop osteonecrosis of the jaw while[0m
[31mon bisphosphonate therapy should receive care by an oral surgeon. In these patients, extensive dental surgery to treat ONJ may exacerbate the condition. Discontinuation of bisphosphonate therapy [0m
[31mshould be considered based on individual benefit/risk assessment. [0m[1;31m5.5[0m[31m Atypical Subtrochanteric and Diaphyseal Femoral Fractures Atypical, low-energy, or low trauma fractures of the femoral shaft have [0m
[31mbeen reported in bisphosphonate-treated patients. These fractures can occur anywhere in the femoral shaft from just below the lesser trochanter to above the supracondylar flare and are transverse or [0m
[31mshort oblique in orientation without evidence of comminution. ALENDRONATE: warnings_and_cautions: Causality has not been established as these fractures also occur in osteoporotic patients who have not[0m
[31mbeen treated with bisphosphonates. Atypical femur fractures most commonly occur with minimal or no trauma to the affected area. They may be bilateral and many patients report prodromal pain in the [0m
[31maffected area, usually presenting as dull, aching thigh pain, weeks to months before a complete fracture occurs. A number of reports note that patients were also receiving treatment with [0m
[31mglucocorticoids [0m[1;31m([0m[31me.g., prednisone[0m[1;31m)[0m[31m at the time of fracture. Any patient with a history of bisphosphonate exposure who presents with thigh or groin pain should be suspected of having an atypical [0m
[31mfracture and should be evaluated to rule out an incomplete femur fracture. Patients presenting with an atypical fracture should also be assessed for symptoms and signs of fracture in the contralateral[0m
[31mlimb.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: warnings_and_cautions: [0m[1;31m5[0m[31m WARNINGS AND PRECAUTIONS Upper Gastrointestinal Adverse Reactions can occur. Instruct patients to follow dosing instructions. Discontinue if new or [0m
[31mworsening symptoms occur. [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[31m Hypocalcemia can worsen and must be corrected prior to use. [0m[1;31m([0m[31m [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m Severe Bone, Joint, Muscle Pain may occur. Discontinue use if severe symptoms develop. [0m[1;31m([0m[31m [0m[1;31m5.3[0m[31m [0m[1;31m)[0m[31m [0m
[31mOsteonecrosis of the Jaw has been reported. [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[31m Atypical Femur Fractures have been reported. Patients with new thigh or groin pain should be evaluated to rule out a femoral fracture. [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[31m [0m
[31mSodium Content: Each tablet contains [0m[1;31m603[0m[31m mg sodium, equivalent to [0m[1;31m1532[0m[31m mg NaCl. Use caution in patients on sodium restriction. [0m[1;31m([0m[31m [0m[1;31m5.7[0m[31m [0m[1;31m)[0m[31m [0m[1;31m5[0m[31m. ALENDRONATE: warnings_and_cautions: [0m[1;31m1[0m[31m Upper Gastrointestinal [0m
[31mAdverse Reactions BINOSTO, like other bisphosphonates administered orally, may cause local irritation of the upper gastrointestinal mucosa. Because of these possible irritant effects and a potential [0m
[31mfor worsening of the underlying disease, caution should be used when BINOSTO is given to patients with active upper gastrointestinal problems [0m[1;31m([0m[31msuch as known Barrett's esophagus, dysphagia, other [0m
[31mesophageal diseases, gastritis, duodenitis, or ulcers[0m[1;31m)[0m[31m. Esophageal adverse experiences, such as esophagitis, esophageal ulcers and esophageal erosions, occasionally with bleeding and rarely followed [0m
[31mby esophageal stricture or perforation, have been reported in patients receiving treatment with oral bisphosphonates including alendronate sodium. In some cases these have been severe and required [0m
[31mhospitalization. ALENDRONATE: warnings_and_cautions: Physicians should therefore be alert to any signs or symptoms signaling a possible esophageal reaction and patients should be instructed to [0m
[31mdiscontinue BINOSTO and seek medical attention if they develop dysphagia, odynophagia, retrosternal pain or new or worsening heartburn. The risk of severe esophageal adverse experiences appears to be [0m
[31mgreater in patients who lie down after taking oral bisphosphonates including alendronate sodium, and/or who continue to take oral bisphosphonates including alendronate sodium after developing symptoms[0m
[31msuggestive of esophageal irritation. Therefore, it is very important that the full dosing instructions are provided to, and understood by, the patient [0m[31m . In patients who cannot comply with dosing [0m
[31minstructions due to mental disability, therapy with BINOSTO should be used under appropriate supervision.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: adverse_reactions_table: [0m[1;31m0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Dyspepsia<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.7[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.2[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Acid regurgitation<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.9[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> [0m
[31mNausea<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.9[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Abdominal distention<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Constipation<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.8[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.6[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> [0m
[31mFlatulence<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.6[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Gastritis<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.2[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1[0m[31m. ALENDRONATE: adverse_reactions_table: [0m[1;31m1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Gastric ulcer<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m
[31mcolspan[0m[31m=[0m[31m"3"[0m[31m>Musculoskeletal<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Musculoskeletal [0m[1;31m([0m[31mbone, muscle, joint[0m[1;31m)[0m[31m pain<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.9[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m3.2[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Muscle cramp<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.2[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1[0m[31m. ALENDRONATE: [0m
[31madverse_reactions_table: [0m[1;31m1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[1;31m>[0m[31m         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32m DO-NOT-KNOW[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE increase the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ALENDRONATE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does ALENDRONATE increase the risk of aplastic [0m
[31manemia?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ALENDRONATE increase the risk of aplastic anemia?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ALENDRONATE increase the risk of aplastic anemia?[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE increase the risk of aplastic anemia?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE increase the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ALENDRONATE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: ALENDRONATE: adverse_reactions: [0m[1;31m1[0m[31m [0m[1;31m1.8[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.2[0m[31m Diarrhea [0m[1;31m3.1[0m[31m [0m[1;31m1.8[0m[31m [0m[1;31m0.6[0m[31m [0m[1;31m0.3[0m[31m Flatulence [0m[1;31m2.6[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m0.2[0m[31m [0m[1;31m0.3[0m[31m Acid regurgitation [0m[1;31m2.0[0m[31m [0m[1;31m4.3[0m[31m [0m[1;31m1.1[0m[31m [0m[1;31m0.9[0m[31m Esophageal ulcer [0m[1;31m1.5[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.1[0m[31m [0m[1;31m0.1[0m[31m Vomiting [0m[1;31m1.0[0m[31m [0m[1;31m1.5[0m[31m [0m[1;31m0.2[0m[31m [0m[1;31m0.3[0m[31m [0m
[31mDysphagia [0m[1;31m1.0[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.1[0m[31m [0m[1;31m0.1[0m[31m Abdominal distention [0m[1;31m1.0[0m[31m [0m[1;31m0.8[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.0[0m[31m Gastritis [0m[1;31m0.5[0m[31m [0m[1;31m1.3[0m[31m [0m[1;31m0.6[0m[31m [0m[1;31m0.7[0m[31m Musculoskeletal Musculoskeletal [0m[1;31m([0m[31mbone, muscle or joint[0m[1;31m)[0m[31m pain [0m[1;31m4.1[0m[31m [0m[1;31m2.5[0m[31m [0m[1;31m0.4[0m[31m [0m[1;31m0[0m[31m. ALENDRONATE: adverse_reactions: [0m[1;31m3[0m[31m [0m
[31mMuscle cramp [0m[1;31m0.0[0m[31m [0m[1;31m1.0[0m[31m [0m[1;31m0.2[0m[31m [0m[1;31m0.1[0m[31m Nervous system/psychiatric Headache [0m[1;31m2.6[0m[31m [0m[1;31m1.5[0m[31m [0m[1;31m0.2[0m[31m [0m[1;31m0.2[0m[31m Dizziness [0m[1;31m0.0[0m[31m [0m[1;31m1.0[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.1[0m[31m Special senses Taste perversion [0m[1;31m0.5[0m[31m [0m[1;31m1.0[0m[31m [0m[1;31m0.1[0m[31m [0m[1;31m0.0[0m[31m Rarely, rash and erythema have occurred. [0m
[31mGastrointestinal Adverse Reactions: One patient treated with alendronate sodium [0m[1;31m([0m[1;31m10[0m[31m mg/day[0m[1;31m)[0m[31m, who had a history of peptic ulcer disease and gastrectomy and who was taking concomitant aspirin developed [0m
[31man anastomotic ulcer with mild hemorrhage, which was considered drug related. Aspirin and alendronate sodium were discontinued and the patient recovered. ALENDRONATE: adverse_reactions: In the Study [0m[1;31m1[0m
[31mand Study [0m[1;31m2[0m[31m populations, [0m[1;31m49[0m[31m-[0m[1;31m54[0m[31m% had a history of gastrointestinal disorders at baseline and [0m[1;31m54[0m[31m-[0m[1;31m89[0m[31m% used nonsteroidal anti-inflammatory drugs or aspirin at some time during the studies [0m[1;31m[[0m[31m see Warnings [0m
[31mand Precautions [0m[1;31m([0m[1;31m5.1[0m[1;31m)[0m[31m [0m[1;31m][0m[31m. Laboratory Test Findings: In double-blind, multicenter, controlled studies, asymptomatic, mild, and transient decreases in serum calcium and phosphate were observed in [0m
[31mapproximately [0m[1;31m18[0m[31m% and [0m[1;31m10[0m[31m%, respectively, of patients taking alendronate versus approximately [0m[1;31m12[0m[31m% and [0m[1;31m3[0m[31m% of those taking placebo. However, the incidences of decreases in serum calcium to less than [0m[1;31m8.0[0m[31m [0m
[31mmg/dL [0m[1;31m([0m[1;31m2.0[0m[31m mM[0m[1;31m)[0m[31m and serum phosphate to less than or equal to [0m[1;31m2.0[0m[31m mg/dL [0m[1;31m([0m[1;31m0.65[0m[31m mM[0m[1;31m)[0m[31m were similar in both treatment groups. ALENDRONATE: adverse_reactions: Weekly Dosing The safety of alendronate sodium [0m[1;31m70[0m
[31mmg once weekly for the treatment of postmenopausal osteoporosis was assessed in a one-year, double-blind, multicenter study comparing alendronate [0m[1;31m70[0m[31m mg once weekly and alendronate [0m[1;31m10[0m[31m mg daily. The [0m
[31moverall safety and tolerability profiles of once weekly alendronate [0m[1;31m70[0m[31m mg and alendronate [0m[1;31m10[0m[31m mg daily were similar. The adverse reactions considered by the investigators as possibly, probably, or [0m
[31mdefinitely drug related in greater than or equal to [0m[1;31m1[0m[31m% of patients in either treatment group are presented in Table [0m[1;31m2[0m[31m. ALENDRONATE: adverse_reactions: Table [0m[1;31m2[0m[31m Osteoporosis Treatment Studies in [0m
[31mPostmenopausal Women Adverse Reactions Considered Possibly, Probably, or Definitely Drug Related by the Investigators and Reported in Greater Than or Equal to [0m[1;31m1[0m[31m% of Patients Once Weekly Alendronate [0m
[31mSodium [0m[1;31m70[0m[31m mg % [0m[1;31m([0m[31mN = [0m[1;31m519[0m[1;31m)[0m[31m Once Daily Alendronate Sodium [0m[1;31m10[0m[31m mg % [0m[1;31m([0m[31mN = [0m[1;31m370[0m[1;31m)[0m[31m Gastrointestinal Abdominal pain [0m[1;31m3.7[0m[31m [0m[1;31m3.0[0m[31m Dyspepsia [0m[1;31m2.7[0m[31m [0m[1;31m2.2[0m[31m Acid regurgitation [0m[1;31m1.9[0m[31m [0m[1;31m2.4[0m[31m Nausea [0m[1;31m1.9[0m[31m [0m[1;31m2.4[0m[31m Abdominal distention [0m[1;31m1.0[0m[31m [0m
[1;31m1.4[0m[31m Constipation [0m[1;31m0.8[0m[31m [0m[1;31m1.6[0m[31m Flatulence [0m[1;31m0.4[0m[31m [0m[1;31m1.6[0m[31m Gastritis [0m[1;31m0.2[0m[31m [0m[1;31m1.1[0m[31m Gastric ulcer [0m[1;31m0.0[0m[31m [0m[1;31m1[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: adverse_reactions: [0m[1;31m0[0m[31m Abdominal pain [0m[1;31m2.1[0m[31m [0m[1;31m1.1[0m[31m [0m[1;31m0.9[0m[31m [0m[1;31m3.4[0m[31m Nausea [0m[1;31m2.1[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m6.2[0m[31m Post-Marketing Experience The following adverse reactions have been identified during post-approval[0m
[31muse of alendronate sodium. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal [0m
[31mrelationship to drug exposure. Body as a Whole : hypersensitivity reactions including urticaria and angioedema. Transient symptoms of myalgia, malaise, asthenia and fever have been reported with [0m
[31malendronate, typically in association with initiation of treatment. Symptomatic hypocalcemia has occurred, generally in association with predisposing conditions. Peripheral edema. ALENDRONATE: [0m
[31madverse_reactions: Gastrointestinal : esophagitis, esophageal erosions, esophageal ulcers, esophageal stricture or perforation, and oropharyngeal ulceration. Gastric or duodenal ulcers, some severe [0m
[31mand with complications have also been reported [0m[31m . Dental : Localized osteonecrosis of the jaw, generally associated with tooth extraction and/or local infection with delayed healing, has been reported[0m
[31m. Musculoskeletal : bone, joint, and/or muscle pain, occasionally severe and incapacitating [0m[31m ; joint swelling; low-energy femoral shaft and subtrochanteric fractures [0m[31m . Nervous system : dizziness and [0m
[31mvertigo. ALENDRONATE: adverse_reactions: Pulmonary: acute asthma exacerbations Skin : rash [0m[1;31m([0m[31moccasionally with photosensitivity[0m[1;31m)[0m[31m, pruritus, alopecia, severe skin reactions, including Stevens-Johnson [0m
[31msyndrome and toxic epidermal necrolysis. Special Senses : uveitis, scleritis or episcleritis. Cholesteatoma of the external auditory canal [0m[1;31m([0m[31mfocal osteonecrosis[0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: adverse_reactions_table: >[0m[1;31m10[0m[31m mg % [0m[1;31m([0m[31mN = [0m[1;31m146[0m[1;31m)[0m[1;31m<[0m[31m/[0m[31mth[0m[31m><th>Placebo % [0m[1;31m([0m[31mN = [0m[1;31m95[0m[1;31m)[0m[31m<[0m[31m/[0m[31mth[0m[31m><th>[0m[1;31m70[0m[31m mg % [0m[1;31m([0m[31mN = [0m[1;31m109[0m[1;31m)[0m[31m<[0m[31m/[0m[31mth[0m[31m><th>Placebo % [0m[1;31m([0m[31mN = [0m[1;31m58[0m[1;31m)[0m[31m<[0m[31m/[0m[31mth[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mthead[0m[31m><tbody><tr><td [0m
[31mcolspan[0m[31m=[0m[31m"5"[0m[31m>Gastrointestinal<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Acid regurgitation<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m4.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m3.2[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> [0m
[31mFlatulence<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m4.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Gastroesophageal reflux disease<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.7[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m3.2[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2[0m[31m. ALENDRONATE: adverse_reactions_table: [0m
[1;31m8[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Dyspepsia<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m3.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.8[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.7[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Diarrhea<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.8[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Abdominal [0m
[31mpain<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.9[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m3.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Nausea<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0[0m[31m. ALENDRONATE: adverse_reactions_table: [0m[1;31m0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[31m>         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: openfda: spl_set_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: contraindications: [0m[1;31m4[0m[31m CONTRAINDICATIONS BINOSTO is contraindicated in patients with the following conditions: Abnormalities of the esophagus which delay esophageal emptying such [0m
[31mas stricture or achalasia [0m[31m Inability to stand or sit upright for at least [0m[1;31m30[0m[31m minutes [0m[31m Do not administer BINOSTO to patients at increased risk of aspiration Hypocalcemia [0m[31m Hypersensitivity to any [0m
[31mcomponent of this product. Hypersensitivity reactions including urticaria and angioedema have been reported [0m[31m . Abnormalities of the esophagus which delay emptying such as stricture or achalasia [0m[1;31m([0m[31m [0m[1;31m4[0m[31m , [0m
[1;31m5[0m[31m. ALENDRONATE: contraindications: [0m[1;31m1[0m[31m [0m[1;31m)[0m[31m Inability to stand/sit upright for at least [0m[1;31m30[0m[31m minutes [0m[1;31m([0m[31m [0m[1;31m4[0m[31m , [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[31m Increased risk of aspiration. [0m[1;31m([0m[31m [0m[1;31m4[0m[31m [0m[1;31m)[0m[31m Hypocalcemia [0m[1;31m([0m[31m [0m[1;31m4[0m[31m , [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m Hypersensitivity to any component[0m
[31mof this product [0m[1;31m([0m[31m [0m[1;31m4[0m[31m , [0m[1;31m6[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: animal_pharmacology_and_or_toxicology: [0m[1;31m13.2[0m[31m Animal Toxicology and/or Pharmacology The relative inhibitory activities on bone resorption and mineralization of alendronate and [0m
[31metidronate were compared in the Schenk assay, which is based on histological examination of the epiphyses of growing rats. In this assay, the lowest dose of alendronate that interfered with bone [0m
[31mmineralization [0m[1;31m([0m[31mleading to osteomalacia[0m[1;31m)[0m[31m was [0m[1;31m6000[0m[31m-fold the antiresorptive dose. The corresponding ratio for etidronate was one to one. These data suggest that alendronate administered in therapeutic [0m
[31mdoses is highly unlikely to induce osteomalacia.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: nonclinical_toxicology: [0m[1;31m13[0m[31m NONCLINICAL TOXICOLOGY [0m[1;31m13.1[0m[31m Carcinogenesis, Mutagenesis, Impairment of Fertility Harderian gland [0m[1;31m([0m[31ma retro-orbital gland not present in humans[0m[1;31m)[0m[31m adenomas[0m
[31mwere increased in high-dose female mice [0m[1;31m([0m[31mp[0m[31m=[0m[1;31m0[0m[1;31m.003[0m[1;31m)[0m[31m in a [0m[1;31m92[0m[31m-week oral carcinogenicity study at doses of alendronate of [0m[1;31m1[0m[31m, [0m[1;31m3[0m[31m, and [0m[1;31m10[0m[31m mg/kg/day [0m[1;31m([0m[31mmales[0m[1;31m)[0m[31m or [0m[1;31m1[0m[31m, [0m[1;31m2[0m[31m, and [0m[1;31m5[0m[31m mg/kg/day [0m[1;31m([0m[31mfemales[0m[1;31m)[0m[31m. These doses are [0m
[31mequivalent to [0m[1;31m0.12[0m[31m to [0m[1;31m1.2[0m[31m times a maximum recommended daily dose of [0m[1;31m40[0m[31m mg, based on surface area, mg/m [0m[1;31m2[0m[31m . The relevance of this finding to humans is unknown. Parafollicular cell [0m[1;31m([0m[31mthyroid[0m[1;31m)[0m[31m adenomas [0m
[31mwere increased in high-dose male rats [0m[1;31m([0m[31mp[0m[31m=[0m[1;31m0[0m[31m. ALENDRONATE: nonclinical_toxicology: [0m[1;31m003[0m[1;31m)[0m[31m in a [0m[1;31m2[0m[31m-year oral carcinogenicity study at doses of [0m[1;31m1[0m[31m and [0m[1;31m3.75[0m[31m mg/kg body weight. These doses are equivalent to [0m
[1;31m0.26[0m[31m and [0m[1;31m1[0m[31m times a [0m[1;31m40[0m[31m mg human daily dose based on surface area, mg/m [0m[1;31m2[0m[31m . The relevance of this finding to humans is unknown. Alendronate sodium was not genotoxic in the in vitro microbial mutagenesis[0m
[31massay with and without metabolic activation, in an in vitro mammalian cell mutagenesis assay, in an in vitro alkaline elution assay in rat hepatocytes, and in an in vivo chromosomal aberration assay [0m
[31min mice. In an in vitro chromosomal aberration assay in Chinese hamster ovary cells, however, alendronate gave equivocal results. Alendronate sodium had no effect on fertility [0m[1;31m([0m[31mmale or female[0m[1;31m)[0m[31m in rats[0m
[31mat oral doses up to [0m[1;31m5[0m[31m mg/kg/day [0m[1;31m([0m[1;31m1[0m[31m. ALENDRONATE: nonclinical_toxicology: [0m[1;31m3[0m[31m times a [0m[1;31m40[0m[31m mg human daily dose based on surface area, mg/m [0m[1;31m2[0m[31m [0m[1;31m)[0m[31m. [0m[1;31m13.2[0m[31m Animal Toxicology and/or Pharmacology The relative [0m
[31minhibitory activities on bone resorption and mineralization of alendronate and etidronate were compared in the Schenk assay, which is based on histological examination of the epiphyses of growing [0m
[31mrats. In this assay, the lowest dose of alendronate that interfered with bone mineralization [0m[1;31m([0m[31mleading to osteomalacia[0m[1;31m)[0m[31m was [0m[1;31m6000[0m[31m-fold the antiresorptive dose. The corresponding ratio for etidronate was[0m
[31mone to one. These data suggest that alendronate administered in therapeutic doses is highly unlikely to induce osteomalacia.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: clinical_pharmacology: [0m[1;31m12[0m[31m CLINICAL PHARMACOLOGY [0m[1;31m12.1[0m[31m Mechanism of Action Animal studies have indicated the following mode of action. At the cellular level, alendronate shows [0m
[31mpreferential localization to sites of bone resorption, specifically under osteoclasts. The osteoclasts adhere normally to the bone surface but lack the ruffled border that is indicative of active [0m
[31mresorption. Alendronate does not interfere with osteoclast recruitment or attachment, but it does inhibit osteoclast activity. Studies in mice on the localization of radioactive [0m[1;31m[[0m[31m [0m[1;31m3[0m[31m H[0m[1;31m][0m[31malendronate in [0m
[31mbone showed about [0m[1;31m10[0m[31m-fold higher uptake on osteoclast surfaces than on osteoblast surfaces. Bones examined [0m[1;31m6[0m[31m and [0m[1;31m49[0m[31m days after [0m[1;31m[[0m[31m [0m[1;31m3[0m[31m H[0m[1;31m][0m[31malendronate administration in rats and mice, respectively, showed [0m
[31mthat normal bone was formed on top of the alendronate, which was incorporated inside the matrix. ALENDRONATE: clinical_pharmacology: While incorporated in bone matrix, alendronate is not [0m
[31mpharmacologically active. Thus, alendronate must be continuously administered to suppress osteoclasts on newly formed resorption surfaces. Histomorphometry in baboons and rats showed that alendronate [0m
[31mtreatment reduces bone turnover [0m[1;31m([0m[31mi.e., the number of sites at which bone is remodeled[0m[1;31m)[0m[31m. In addition, bone formation exceeds bone resorption at these remodeling sites, leading to progressive gains in [0m
[31mbone mass. [0m[1;31m12.2[0m[31m Pharmacodynamics Alendronate is a bisphosphonate that binds to bone hydroxyapatite and specifically inhibits the activity of osteoclasts, the bone-resorbing cells. Alendronate reduces [0m
[31mbone resorption with no direct effect on bone formation, although the latter process is ultimately reduced because bone resorption and formation are coupled during bone turnover. ALENDRONATE: [0m
[31mclinical_pharmacology: Osteoporosis in Postmenopausal Women Osteoporosis is characterized by low bone mass that leads to an increased risk of fracture. The diagnosis can be confirmed by the finding of[0m
[31mlow bone mass, evidence of fracture on x-ray, a history of osteoporotic fracture, or height loss or kyphosis, indicative of vertebral [0m[1;31m([0m[31mspinal[0m[1;31m)[0m[31m fracture. Osteoporosis occurs in both males and females [0m
[31mbut is most common among women following the menopause, when bone turnover increases and the rate of bone resorption exceeds that of bone formation. These changes result in progressive bone loss and [0m
[31mlead to osteoporosis in a significant proportion of women over age [0m[1;31m50[0m[31m. Fractures, usually of the spine, hip, and wrist, are the common consequences. From age [0m[1;31m50[0m[31m to age [0m[1;31m90[0m[31m, the risk of hip fracture in [0m
[31mwhite women increases [0m[1;31m50[0m[31m-fold and the risk of vertebral fracture [0m[1;31m15[0m[31m- to [0m[1;31m30[0m[31m-fold. ALENDRONATE: clinical_pharmacology: It is estimated that approximately [0m[1;31m40[0m[31m% of [0m[1;31m50[0m[31m-year-old women will sustain one or [0m
[31mmore osteoporosis-related fractures of the spine, hip, or wrist during their remaining lifetimes. Hip fractures, in particular, are associated with substantial morbidity, disability, and mortality. [0m
[31mDaily oral doses of alendronate sodium [0m[1;31m([0m[1;31m5[0m[31m, [0m[1;31m20[0m[31m, and [0m[1;31m40[0m[31m mg for six weeks[0m[1;31m)[0m[31m in postmenopausal women produced biochemical changes indicative of dose-dependent inhibition of bone resorption, including [0m
[31mdecreases in urinary calcium and urinary markers of bone collagen degradation [0m[1;31m([0m[31msuch as deoxypyridinoline and cross-linked N-telopeptides of type I collagen[0m[1;31m)[0m[31m. These biochemical changes tended to return[0m
[31mtoward baseline values as early as [0m[1;31m3[0m[31m weeks following the discontinuation of therapy with alendronate and did not differ from placebo after [0m[1;31m7[0m[31m months. ALENDRONATE: clinical_pharmacology: Long-term [0m
[31mtreatment of osteoporosis with alendronate sodium [0m[1;31m10[0m[31m mg/day [0m[1;31m([0m[31mfor up to five years[0m[1;31m)[0m[31m reduced urinary excretion of markers of bone resorption, deoxypyridinoline and cross-linked N-telopeptides of type l [0m
[31mcollagen, by approximately [0m[1;31m50[0m[31m% and [0m[1;31m70[0m[31m%, respectively, to reach levels similar to those seen in healthy premenopausal women. Similar decreases were seen in patients in osteoporosis prevention studies [0m
[31mwho received alendronate sodium [0m[1;31m5[0m[31m mg/day. The decrease in the rate of bone resorption indicated by these markers was evident as early as [0m[1;31m1[0m[31m month and at [0m[1;31m3[0m[31m to [0m[1;31m6[0m[31m months reached a plateau that was [0m
[31mmaintained for the entire duration of treatment with alendronate sodium.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: indications_and_usage: [0m[1;31m1[0m[31m INDICATIONS AND USAGE BINOSTO is a bisphosphonate indicated for: Treatment of osteoporosis in postmenopausal women [0m[1;31m([0m[31m [0m[1;31m1.1[0m[31m [0m[1;31m)[0m[31m Treatment to increase bone [0m
[31mmass in men with osteoporosis [0m[1;31m([0m[31m [0m[1;31m1.2[0m[31m [0m[1;31m)[0m[31m Limitation of use: Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after [0m[1;31m3[0m[31m to [0m[1;31m5[0m[31m years of use[0m
[1;31m([0m[31m [0m[1;31m1.3[0m[31m [0m[1;31m)[0m[31m [0m[1;31m1.1[0m[31m Treatment of Osteoporosis in Postmenopausal Women BINOSTO effervescent tablet [0m[1;31m70[0m[31m mg is indicated for the treatment of osteoporosis in postmenopausal women. For the treatment of [0m
[31mosteoporosis, alendronate sodium increases bone mass and reduces the incidence of fractures, including those of the hip and spine [0m[1;31m([0m[31mvertebral compression fractures[0m[1;31m)[0m[31m. [0m[1;31m[[0m[31mSee Clinical Studies [0m[1;31m([0m[1;31m14.1[0m[1;31m)[0m[31m .[0m[1;31m][0m[31m [0m[1;31m1[0m[31m. [0m
[31mALENDRONATE: indications_and_usage: [0m[1;31m2[0m[31m Treatment to Increase Bone Mass in Men With Osteoporosis BINOSTO is indicated for treatment to increase bone mass in men with osteoporosis [0m[31m . [0m[1;31m1.3[0m[31m Important [0m
[31mLimitations of Use The optimal duration of use has not been determined. The safety and effectiveness of BINOSTO for the treatment of osteoporosis are based on clinical data of four years duration. All[0m
[31mpatients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after [0m[1;31m3[0m[31m [0m
[31mto [0m[1;31m5[0m[31m years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: warnings_and_cautions: There have been post-marketing reports of gastric and duodenal ulcers with oral bisphosphonate use, some severe and with complications, although no [0m
[31mincreased risk was observed in controlled clinical trials [0m[31m . [0m[1;31m5.2[0m[31m Mineral Metabolism Hypocalcemia must be corrected before initiating therapy with BINOSTO [0m[31m. Other disorders affecting mineral metabolism[0m
[1;31m([0m[31msuch as vitamin D deficiency[0m[1;31m)[0m[31m should also be effectively treated. In patients with these conditions, serum calcium and symptoms of hypocalcemia should be monitored during therapy with BINOSTO. [0m
[31mPresumably due to the effects of BINOSTO on increasing bone mineral, small, asymptomatic decreases in serum calcium and phosphate may occur. Patients should receive adequate calcium and vitamin D [0m
[31mintake. [0m[1;31m5[0m[31m. ALENDRONATE: warnings_and_cautions: [0m[1;31m3[0m[31m Musculoskeletal Pain In post-marketing experience, severe and occasionally incapacitating bone, joint, and/or muscle pain has been reported in patients[0m
[31mtaking bisphosphonates that are approved for the treatment of osteoporosis [0m[31m . This category of drugs includes BINOSTO. Most of the patients were postmenopausal women. The time to onset of symptoms [0m
[31mvaried from one day to several months after starting the drug. Discontinue use if severe symptoms develop. Most patients had relief of symptoms after stopping. A subset had recurrence of symptoms when[0m
[31mrechallenged with the same drug or another bisphosphonate. In placebo-controlled clinical studies of alendronate sodium, the percentages of patients with these symptoms were similar in the alendronate[0m
[31msodium and placebo groups. [0m[1;31m5[0m[31m. ALENDRONATE: warnings_and_cautions: [0m[1;31m4[0m[31m Osteonecrosis of the Jaw Osteonecrosis of the jaw [0m[1;31m([0m[31mONJ[0m[1;31m)[0m[31m, which can occur spontaneously, is generally associated with tooth [0m
[31mextraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates, including alendronate sodium. Known risk factors for osteonecrosis of the jaw include [0m
[31minvasive dental procedures [0m[1;31m([0m[31me.g., tooth extraction, dental implants, boney surgery[0m[1;31m)[0m[31m, diagnosis of cancer, concomitant therapies [0m[1;31m([0m[31me.g., chemotherapy, corticosteroids, angiogenesis inhibitors[0m[1;31m)[0m[31m, poor [0m
[31moral hygiene, and co-morbid disorders [0m[1;31m([0m[31me.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures[0m[1;31m)[0m[31m. The risk of ONJ may increase with duration of[0m
[31mexposure to bisphosphonates. For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ. ALENDRONATE: warnings_and_cautions: Clinical [0m
[31mjudgment of the treating physician and/or oral surgeon should guide the management plan of each patient based on individual benefit/risk assessment. Patients who develop osteonecrosis of the jaw while[0m
[31mon bisphosphonate therapy should receive care by an oral surgeon. In these patients, extensive dental surgery to treat ONJ may exacerbate the condition. Discontinuation of bisphosphonate therapy [0m
[31mshould be considered based on individual benefit/risk assessment. [0m[1;31m5.5[0m[31m Atypical Subtrochanteric and Diaphyseal Femoral Fractures Atypical, low-energy, or low trauma fractures of the femoral shaft have [0m
[31mbeen reported in bisphosphonate-treated patients. These fractures can occur anywhere in the femoral shaft from just below the lesser trochanter to above the supracondylar flare and are transverse or [0m
[31mshort oblique in orientation without evidence of comminution. ALENDRONATE: warnings_and_cautions: Causality has not been established as these fractures also occur in osteoporotic patients who have not[0m
[31mbeen treated with bisphosphonates. Atypical femur fractures most commonly occur with minimal or no trauma to the affected area. They may be bilateral and many patients report prodromal pain in the [0m
[31maffected area, usually presenting as dull, aching thigh pain, weeks to months before a complete fracture occurs. A number of reports note that patients were also receiving treatment with [0m
[31mglucocorticoids [0m[1;31m([0m[31me.g., prednisone[0m[1;31m)[0m[31m at the time of fracture. Any patient with a history of bisphosphonate exposure who presents with thigh or groin pain should be suspected of having an atypical [0m
[31mfracture and should be evaluated to rule out an incomplete femur fracture. Patients presenting with an atypical fracture should also be assessed for symptoms and signs of fracture in the contralateral[0m
[31mlimb.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: warnings_and_cautions: [0m[1;31m5[0m[31m WARNINGS AND PRECAUTIONS Upper Gastrointestinal Adverse Reactions can occur. Instruct patients to follow dosing instructions. Discontinue if new or [0m
[31mworsening symptoms occur. [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[31m Hypocalcemia can worsen and must be corrected prior to use. [0m[1;31m([0m[31m [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m Severe Bone, Joint, Muscle Pain may occur. Discontinue use if severe symptoms develop. [0m[1;31m([0m[31m [0m[1;31m5.3[0m[31m [0m[1;31m)[0m[31m [0m
[31mOsteonecrosis of the Jaw has been reported. [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[31m Atypical Femur Fractures have been reported. Patients with new thigh or groin pain should be evaluated to rule out a femoral fracture. [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[31m [0m
[31mSodium Content: Each tablet contains [0m[1;31m603[0m[31m mg sodium, equivalent to [0m[1;31m1532[0m[31m mg NaCl. Use caution in patients on sodium restriction. [0m[1;31m([0m[31m [0m[1;31m5.7[0m[31m [0m[1;31m)[0m[31m [0m[1;31m5[0m[31m. ALENDRONATE: warnings_and_cautions: [0m[1;31m1[0m[31m Upper Gastrointestinal [0m
[31mAdverse Reactions BINOSTO, like other bisphosphonates administered orally, may cause local irritation of the upper gastrointestinal mucosa. Because of these possible irritant effects and a potential [0m
[31mfor worsening of the underlying disease, caution should be used when BINOSTO is given to patients with active upper gastrointestinal problems [0m[1;31m([0m[31msuch as known Barrett's esophagus, dysphagia, other [0m
[31mesophageal diseases, gastritis, duodenitis, or ulcers[0m[1;31m)[0m[31m. Esophageal adverse experiences, such as esophagitis, esophageal ulcers and esophageal erosions, occasionally with bleeding and rarely followed [0m
[31mby esophageal stricture or perforation, have been reported in patients receiving treatment with oral bisphosphonates including alendronate sodium. In some cases these have been severe and required [0m
[31mhospitalization. ALENDRONATE: warnings_and_cautions: Physicians should therefore be alert to any signs or symptoms signaling a possible esophageal reaction and patients should be instructed to [0m
[31mdiscontinue BINOSTO and seek medical attention if they develop dysphagia, odynophagia, retrosternal pain or new or worsening heartburn. The risk of severe esophageal adverse experiences appears to be [0m
[31mgreater in patients who lie down after taking oral bisphosphonates including alendronate sodium, and/or who continue to take oral bisphosphonates including alendronate sodium after developing symptoms[0m
[31msuggestive of esophageal irritation. Therefore, it is very important that the full dosing instructions are provided to, and understood by, the patient [0m[31m . In patients who cannot comply with dosing [0m
[31minstructions due to mental disability, therapy with BINOSTO should be used under appropriate supervision.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: adverse_reactions_table: [0m[1;31m0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Dyspepsia<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.7[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.2[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Acid regurgitation<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.9[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> [0m
[31mNausea<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.9[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Abdominal distention<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Constipation<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.8[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.6[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> [0m
[31mFlatulence<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.6[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Gastritis<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.2[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1[0m[31m. ALENDRONATE: adverse_reactions_table: [0m[1;31m1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Gastric ulcer<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m
[31mcolspan[0m[31m=[0m[31m"3"[0m[31m>Musculoskeletal<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Musculoskeletal [0m[1;31m([0m[31mbone, muscle, joint[0m[1;31m)[0m[31m pain<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.9[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m3.2[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Muscle cramp<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.2[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1[0m[31m. ALENDRONATE: [0m
[31madverse_reactions_table: [0m[1;31m1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[1;31m>[0m[31m         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ALENDRONATE increase the risk of aplastic anemia?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ALENDRONATE increase the risk of aplastic anemia?[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE increase the risk of aplastic anemia?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE increase the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ALENDRONATE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does ALENDRONATE increase the risk of aplastic [0m
[31manemia?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ALENDRONATE increase the risk of aplastic anemia?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ALENDRONATE increase the risk of aplastic anemia?[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE increase the risk of aplastic anemia?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE increase the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ALENDRONATE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: ALENDRONATE: adverse_reactions: [0m[1;31m1[0m[31m [0m[1;31m1.8[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.2[0m[31m Diarrhea [0m[1;31m3.1[0m[31m [0m[1;31m1.8[0m[31m [0m[1;31m0.6[0m[31m [0m[1;31m0.3[0m[31m Flatulence [0m[1;31m2.6[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m0.2[0m[31m [0m[1;31m0.3[0m[31m Acid regurgitation [0m[1;31m2.0[0m[31m [0m[1;31m4.3[0m[31m [0m[1;31m1.1[0m[31m [0m[1;31m0.9[0m[31m Esophageal ulcer [0m[1;31m1.5[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.1[0m[31m [0m[1;31m0.1[0m[31m Vomiting [0m[1;31m1.0[0m[31m [0m[1;31m1.5[0m[31m [0m[1;31m0.2[0m[31m [0m[1;31m0.3[0m[31m [0m
[31mDysphagia [0m[1;31m1.0[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.1[0m[31m [0m[1;31m0.1[0m[31m Abdominal distention [0m[1;31m1.0[0m[31m [0m[1;31m0.8[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.0[0m[31m Gastritis [0m[1;31m0.5[0m[31m [0m[1;31m1.3[0m[31m [0m[1;31m0.6[0m[31m [0m[1;31m0.7[0m[31m Musculoskeletal Musculoskeletal [0m[1;31m([0m[31mbone, muscle or joint[0m[1;31m)[0m[31m pain [0m[1;31m4.1[0m[31m [0m[1;31m2.5[0m[31m [0m[1;31m0.4[0m[31m [0m[1;31m0[0m[31m. ALENDRONATE: adverse_reactions: [0m[1;31m3[0m[31m [0m
[31mMuscle cramp [0m[1;31m0.0[0m[31m [0m[1;31m1.0[0m[31m [0m[1;31m0.2[0m[31m [0m[1;31m0.1[0m[31m Nervous system/psychiatric Headache [0m[1;31m2.6[0m[31m [0m[1;31m1.5[0m[31m [0m[1;31m0.2[0m[31m [0m[1;31m0.2[0m[31m Dizziness [0m[1;31m0.0[0m[31m [0m[1;31m1.0[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.1[0m[31m Special senses Taste perversion [0m[1;31m0.5[0m[31m [0m[1;31m1.0[0m[31m [0m[1;31m0.1[0m[31m [0m[1;31m0.0[0m[31m Rarely, rash and erythema have occurred. [0m
[31mGastrointestinal Adverse Reactions: One patient treated with alendronate sodium [0m[1;31m([0m[1;31m10[0m[31m mg/day[0m[1;31m)[0m[31m, who had a history of peptic ulcer disease and gastrectomy and who was taking concomitant aspirin developed [0m
[31man anastomotic ulcer with mild hemorrhage, which was considered drug related. Aspirin and alendronate sodium were discontinued and the patient recovered. ALENDRONATE: adverse_reactions: In the Study [0m[1;31m1[0m
[31mand Study [0m[1;31m2[0m[31m populations, [0m[1;31m49[0m[31m-[0m[1;31m54[0m[31m% had a history of gastrointestinal disorders at baseline and [0m[1;31m54[0m[31m-[0m[1;31m89[0m[31m% used nonsteroidal anti-inflammatory drugs or aspirin at some time during the studies [0m[1;31m[[0m[31m see Warnings [0m
[31mand Precautions [0m[1;31m([0m[1;31m5.1[0m[1;31m)[0m[31m [0m[1;31m][0m[31m. Laboratory Test Findings: In double-blind, multicenter, controlled studies, asymptomatic, mild, and transient decreases in serum calcium and phosphate were observed in [0m
[31mapproximately [0m[1;31m18[0m[31m% and [0m[1;31m10[0m[31m%, respectively, of patients taking alendronate versus approximately [0m[1;31m12[0m[31m% and [0m[1;31m3[0m[31m% of those taking placebo. However, the incidences of decreases in serum calcium to less than [0m[1;31m8.0[0m[31m [0m
[31mmg/dL [0m[1;31m([0m[1;31m2.0[0m[31m mM[0m[1;31m)[0m[31m and serum phosphate to less than or equal to [0m[1;31m2.0[0m[31m mg/dL [0m[1;31m([0m[1;31m0.65[0m[31m mM[0m[1;31m)[0m[31m were similar in both treatment groups. ALENDRONATE: adverse_reactions: Weekly Dosing The safety of alendronate sodium [0m[1;31m70[0m
[31mmg once weekly for the treatment of postmenopausal osteoporosis was assessed in a one-year, double-blind, multicenter study comparing alendronate [0m[1;31m70[0m[31m mg once weekly and alendronate [0m[1;31m10[0m[31m mg daily. The [0m
[31moverall safety and tolerability profiles of once weekly alendronate [0m[1;31m70[0m[31m mg and alendronate [0m[1;31m10[0m[31m mg daily were similar. The adverse reactions considered by the investigators as possibly, probably, or [0m
[31mdefinitely drug related in greater than or equal to [0m[1;31m1[0m[31m% of patients in either treatment group are presented in Table [0m[1;31m2[0m[31m. ALENDRONATE: adverse_reactions: Table [0m[1;31m2[0m[31m Osteoporosis Treatment Studies in [0m
[31mPostmenopausal Women Adverse Reactions Considered Possibly, Probably, or Definitely Drug Related by the Investigators and Reported in Greater Than or Equal to [0m[1;31m1[0m[31m% of Patients Once Weekly Alendronate [0m
[31mSodium [0m[1;31m70[0m[31m mg % [0m[1;31m([0m[31mN = [0m[1;31m519[0m[1;31m)[0m[31m Once Daily Alendronate Sodium [0m[1;31m10[0m[31m mg % [0m[1;31m([0m[31mN = [0m[1;31m370[0m[1;31m)[0m[31m Gastrointestinal Abdominal pain [0m[1;31m3.7[0m[31m [0m[1;31m3.0[0m[31m Dyspepsia [0m[1;31m2.7[0m[31m [0m[1;31m2.2[0m[31m Acid regurgitation [0m[1;31m1.9[0m[31m [0m[1;31m2.4[0m[31m Nausea [0m[1;31m1.9[0m[31m [0m[1;31m2.4[0m[31m Abdominal distention [0m[1;31m1.0[0m[31m [0m
[1;31m1.4[0m[31m Constipation [0m[1;31m0.8[0m[31m [0m[1;31m1.6[0m[31m Flatulence [0m[1;31m0.4[0m[31m [0m[1;31m1.6[0m[31m Gastritis [0m[1;31m0.2[0m[31m [0m[1;31m1.1[0m[31m Gastric ulcer [0m[1;31m0.0[0m[31m [0m[1;31m1[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: adverse_reactions: [0m[1;31m0[0m[31m Abdominal pain [0m[1;31m2.1[0m[31m [0m[1;31m1.1[0m[31m [0m[1;31m0.9[0m[31m [0m[1;31m3.4[0m[31m Nausea [0m[1;31m2.1[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m6.2[0m[31m Post-Marketing Experience The following adverse reactions have been identified during post-approval[0m
[31muse of alendronate sodium. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal [0m
[31mrelationship to drug exposure. Body as a Whole : hypersensitivity reactions including urticaria and angioedema. Transient symptoms of myalgia, malaise, asthenia and fever have been reported with [0m
[31malendronate, typically in association with initiation of treatment. Symptomatic hypocalcemia has occurred, generally in association with predisposing conditions. Peripheral edema. ALENDRONATE: [0m
[31madverse_reactions: Gastrointestinal : esophagitis, esophageal erosions, esophageal ulcers, esophageal stricture or perforation, and oropharyngeal ulceration. Gastric or duodenal ulcers, some severe [0m
[31mand with complications have also been reported [0m[31m . Dental : Localized osteonecrosis of the jaw, generally associated with tooth extraction and/or local infection with delayed healing, has been reported[0m
[31m. Musculoskeletal : bone, joint, and/or muscle pain, occasionally severe and incapacitating [0m[31m ; joint swelling; low-energy femoral shaft and subtrochanteric fractures [0m[31m . Nervous system : dizziness and [0m
[31mvertigo. ALENDRONATE: adverse_reactions: Pulmonary: acute asthma exacerbations Skin : rash [0m[1;31m([0m[31moccasionally with photosensitivity[0m[1;31m)[0m[31m, pruritus, alopecia, severe skin reactions, including Stevens-Johnson [0m
[31msyndrome and toxic epidermal necrolysis. Special Senses : uveitis, scleritis or episcleritis. Cholesteatoma of the external auditory canal [0m[1;31m([0m[31mfocal osteonecrosis[0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: adverse_reactions_table: >[0m[1;31m10[0m[31m mg % [0m[1;31m([0m[31mN = [0m[1;31m146[0m[1;31m)[0m[1;31m<[0m[31m/[0m[31mth[0m[31m><th>Placebo % [0m[1;31m([0m[31mN = [0m[1;31m95[0m[1;31m)[0m[31m<[0m[31m/[0m[31mth[0m[31m><th>[0m[1;31m70[0m[31m mg % [0m[1;31m([0m[31mN = [0m[1;31m109[0m[1;31m)[0m[31m<[0m[31m/[0m[31mth[0m[31m><th>Placebo % [0m[1;31m([0m[31mN = [0m[1;31m58[0m[1;31m)[0m[31m<[0m[31m/[0m[31mth[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mthead[0m[31m><tbody><tr><td [0m
[31mcolspan[0m[31m=[0m[31m"5"[0m[31m>Gastrointestinal<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Acid regurgitation<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m4.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m3.2[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> [0m
[31mFlatulence<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m4.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Gastroesophageal reflux disease<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.7[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m3.2[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2[0m[31m. ALENDRONATE: adverse_reactions_table: [0m
[1;31m8[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Dyspepsia<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m3.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.8[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.7[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Diarrhea<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.8[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Abdominal [0m
[31mpain<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.9[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m3.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Nausea<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0[0m[31m. ALENDRONATE: adverse_reactions_table: [0m[1;31m0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[31m>         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: openfda: spl_set_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: contraindications: [0m[1;31m4[0m[31m CONTRAINDICATIONS BINOSTO is contraindicated in patients with the following conditions: Abnormalities of the esophagus which delay esophageal emptying such [0m
[31mas stricture or achalasia [0m[31m Inability to stand or sit upright for at least [0m[1;31m30[0m[31m minutes [0m[31m Do not administer BINOSTO to patients at increased risk of aspiration Hypocalcemia [0m[31m Hypersensitivity to any [0m
[31mcomponent of this product. Hypersensitivity reactions including urticaria and angioedema have been reported [0m[31m . Abnormalities of the esophagus which delay emptying such as stricture or achalasia [0m[1;31m([0m[31m [0m[1;31m4[0m[31m , [0m
[1;31m5[0m[31m. ALENDRONATE: contraindications: [0m[1;31m1[0m[31m [0m[1;31m)[0m[31m Inability to stand/sit upright for at least [0m[1;31m30[0m[31m minutes [0m[1;31m([0m[31m [0m[1;31m4[0m[31m , [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[31m Increased risk of aspiration. [0m[1;31m([0m[31m [0m[1;31m4[0m[31m [0m[1;31m)[0m[31m Hypocalcemia [0m[1;31m([0m[31m [0m[1;31m4[0m[31m , [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m Hypersensitivity to any component[0m
[31mof this product [0m[1;31m([0m[31m [0m[1;31m4[0m[31m , [0m[1;31m6[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: animal_pharmacology_and_or_toxicology: [0m[1;31m13.2[0m[31m Animal Toxicology and/or Pharmacology The relative inhibitory activities on bone resorption and mineralization of alendronate and [0m
[31metidronate were compared in the Schenk assay, which is based on histological examination of the epiphyses of growing rats. In this assay, the lowest dose of alendronate that interfered with bone [0m
[31mmineralization [0m[1;31m([0m[31mleading to osteomalacia[0m[1;31m)[0m[31m was [0m[1;31m6000[0m[31m-fold the antiresorptive dose. The corresponding ratio for etidronate was one to one. These data suggest that alendronate administered in therapeutic [0m
[31mdoses is highly unlikely to induce osteomalacia.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: nonclinical_toxicology: [0m[1;31m13[0m[31m NONCLINICAL TOXICOLOGY [0m[1;31m13.1[0m[31m Carcinogenesis, Mutagenesis, Impairment of Fertility Harderian gland [0m[1;31m([0m[31ma retro-orbital gland not present in humans[0m[1;31m)[0m[31m adenomas[0m
[31mwere increased in high-dose female mice [0m[1;31m([0m[31mp[0m[31m=[0m[1;31m0[0m[1;31m.003[0m[1;31m)[0m[31m in a [0m[1;31m92[0m[31m-week oral carcinogenicity study at doses of alendronate of [0m[1;31m1[0m[31m, [0m[1;31m3[0m[31m, and [0m[1;31m10[0m[31m mg/kg/day [0m[1;31m([0m[31mmales[0m[1;31m)[0m[31m or [0m[1;31m1[0m[31m, [0m[1;31m2[0m[31m, and [0m[1;31m5[0m[31m mg/kg/day [0m[1;31m([0m[31mfemales[0m[1;31m)[0m[31m. These doses are [0m
[31mequivalent to [0m[1;31m0.12[0m[31m to [0m[1;31m1.2[0m[31m times a maximum recommended daily dose of [0m[1;31m40[0m[31m mg, based on surface area, mg/m [0m[1;31m2[0m[31m . The relevance of this finding to humans is unknown. Parafollicular cell [0m[1;31m([0m[31mthyroid[0m[1;31m)[0m[31m adenomas [0m
[31mwere increased in high-dose male rats [0m[1;31m([0m[31mp[0m[31m=[0m[1;31m0[0m[31m. ALENDRONATE: nonclinical_toxicology: [0m[1;31m003[0m[1;31m)[0m[31m in a [0m[1;31m2[0m[31m-year oral carcinogenicity study at doses of [0m[1;31m1[0m[31m and [0m[1;31m3.75[0m[31m mg/kg body weight. These doses are equivalent to [0m
[1;31m0.26[0m[31m and [0m[1;31m1[0m[31m times a [0m[1;31m40[0m[31m mg human daily dose based on surface area, mg/m [0m[1;31m2[0m[31m . The relevance of this finding to humans is unknown. Alendronate sodium was not genotoxic in the in vitro microbial mutagenesis[0m
[31massay with and without metabolic activation, in an in vitro mammalian cell mutagenesis assay, in an in vitro alkaline elution assay in rat hepatocytes, and in an in vivo chromosomal aberration assay [0m
[31min mice. In an in vitro chromosomal aberration assay in Chinese hamster ovary cells, however, alendronate gave equivocal results. Alendronate sodium had no effect on fertility [0m[1;31m([0m[31mmale or female[0m[1;31m)[0m[31m in rats[0m
[31mat oral doses up to [0m[1;31m5[0m[31m mg/kg/day [0m[1;31m([0m[1;31m1[0m[31m. ALENDRONATE: nonclinical_toxicology: [0m[1;31m3[0m[31m times a [0m[1;31m40[0m[31m mg human daily dose based on surface area, mg/m [0m[1;31m2[0m[31m [0m[1;31m)[0m[31m. [0m[1;31m13.2[0m[31m Animal Toxicology and/or Pharmacology The relative [0m
[31minhibitory activities on bone resorption and mineralization of alendronate and etidronate were compared in the Schenk assay, which is based on histological examination of the epiphyses of growing [0m
[31mrats. In this assay, the lowest dose of alendronate that interfered with bone mineralization [0m[1;31m([0m[31mleading to osteomalacia[0m[1;31m)[0m[31m was [0m[1;31m6000[0m[31m-fold the antiresorptive dose. The corresponding ratio for etidronate was[0m
[31mone to one. These data suggest that alendronate administered in therapeutic doses is highly unlikely to induce osteomalacia.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: clinical_pharmacology: [0m[1;31m12[0m[31m CLINICAL PHARMACOLOGY [0m[1;31m12.1[0m[31m Mechanism of Action Animal studies have indicated the following mode of action. At the cellular level, alendronate shows [0m
[31mpreferential localization to sites of bone resorption, specifically under osteoclasts. The osteoclasts adhere normally to the bone surface but lack the ruffled border that is indicative of active [0m
[31mresorption. Alendronate does not interfere with osteoclast recruitment or attachment, but it does inhibit osteoclast activity. Studies in mice on the localization of radioactive [0m[1;31m[[0m[31m [0m[1;31m3[0m[31m H[0m[1;31m][0m[31malendronate in [0m
[31mbone showed about [0m[1;31m10[0m[31m-fold higher uptake on osteoclast surfaces than on osteoblast surfaces. Bones examined [0m[1;31m6[0m[31m and [0m[1;31m49[0m[31m days after [0m[1;31m[[0m[31m [0m[1;31m3[0m[31m H[0m[1;31m][0m[31malendronate administration in rats and mice, respectively, showed [0m
[31mthat normal bone was formed on top of the alendronate, which was incorporated inside the matrix. ALENDRONATE: clinical_pharmacology: While incorporated in bone matrix, alendronate is not [0m
[31mpharmacologically active. Thus, alendronate must be continuously administered to suppress osteoclasts on newly formed resorption surfaces. Histomorphometry in baboons and rats showed that alendronate [0m
[31mtreatment reduces bone turnover [0m[1;31m([0m[31mi.e., the number of sites at which bone is remodeled[0m[1;31m)[0m[31m. In addition, bone formation exceeds bone resorption at these remodeling sites, leading to progressive gains in [0m
[31mbone mass. [0m[1;31m12.2[0m[31m Pharmacodynamics Alendronate is a bisphosphonate that binds to bone hydroxyapatite and specifically inhibits the activity of osteoclasts, the bone-resorbing cells. Alendronate reduces [0m
[31mbone resorption with no direct effect on bone formation, although the latter process is ultimately reduced because bone resorption and formation are coupled during bone turnover. ALENDRONATE: [0m
[31mclinical_pharmacology: Osteoporosis in Postmenopausal Women Osteoporosis is characterized by low bone mass that leads to an increased risk of fracture. The diagnosis can be confirmed by the finding of[0m
[31mlow bone mass, evidence of fracture on x-ray, a history of osteoporotic fracture, or height loss or kyphosis, indicative of vertebral [0m[1;31m([0m[31mspinal[0m[1;31m)[0m[31m fracture. Osteoporosis occurs in both males and females [0m
[31mbut is most common among women following the menopause, when bone turnover increases and the rate of bone resorption exceeds that of bone formation. These changes result in progressive bone loss and [0m
[31mlead to osteoporosis in a significant proportion of women over age [0m[1;31m50[0m[31m. Fractures, usually of the spine, hip, and wrist, are the common consequences. From age [0m[1;31m50[0m[31m to age [0m[1;31m90[0m[31m, the risk of hip fracture in [0m
[31mwhite women increases [0m[1;31m50[0m[31m-fold and the risk of vertebral fracture [0m[1;31m15[0m[31m- to [0m[1;31m30[0m[31m-fold. ALENDRONATE: clinical_pharmacology: It is estimated that approximately [0m[1;31m40[0m[31m% of [0m[1;31m50[0m[31m-year-old women will sustain one or [0m
[31mmore osteoporosis-related fractures of the spine, hip, or wrist during their remaining lifetimes. Hip fractures, in particular, are associated with substantial morbidity, disability, and mortality. [0m
[31mDaily oral doses of alendronate sodium [0m[1;31m([0m[1;31m5[0m[31m, [0m[1;31m20[0m[31m, and [0m[1;31m40[0m[31m mg for six weeks[0m[1;31m)[0m[31m in postmenopausal women produced biochemical changes indicative of dose-dependent inhibition of bone resorption, including [0m
[31mdecreases in urinary calcium and urinary markers of bone collagen degradation [0m[1;31m([0m[31msuch as deoxypyridinoline and cross-linked N-telopeptides of type I collagen[0m[1;31m)[0m[31m. These biochemical changes tended to return[0m
[31mtoward baseline values as early as [0m[1;31m3[0m[31m weeks following the discontinuation of therapy with alendronate and did not differ from placebo after [0m[1;31m7[0m[31m months. ALENDRONATE: clinical_pharmacology: Long-term [0m
[31mtreatment of osteoporosis with alendronate sodium [0m[1;31m10[0m[31m mg/day [0m[1;31m([0m[31mfor up to five years[0m[1;31m)[0m[31m reduced urinary excretion of markers of bone resorption, deoxypyridinoline and cross-linked N-telopeptides of type l [0m
[31mcollagen, by approximately [0m[1;31m50[0m[31m% and [0m[1;31m70[0m[31m%, respectively, to reach levels similar to those seen in healthy premenopausal women. Similar decreases were seen in patients in osteoporosis prevention studies [0m
[31mwho received alendronate sodium [0m[1;31m5[0m[31m mg/day. The decrease in the rate of bone resorption indicated by these markers was evident as early as [0m[1;31m1[0m[31m month and at [0m[1;31m3[0m[31m to [0m[1;31m6[0m[31m months reached a plateau that was [0m
[31mmaintained for the entire duration of treatment with alendronate sodium.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: indications_and_usage: [0m[1;31m1[0m[31m INDICATIONS AND USAGE BINOSTO is a bisphosphonate indicated for: Treatment of osteoporosis in postmenopausal women [0m[1;31m([0m[31m [0m[1;31m1.1[0m[31m [0m[1;31m)[0m[31m Treatment to increase bone [0m
[31mmass in men with osteoporosis [0m[1;31m([0m[31m [0m[1;31m1.2[0m[31m [0m[1;31m)[0m[31m Limitation of use: Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after [0m[1;31m3[0m[31m to [0m[1;31m5[0m[31m years of use[0m
[1;31m([0m[31m [0m[1;31m1.3[0m[31m [0m[1;31m)[0m[31m [0m[1;31m1.1[0m[31m Treatment of Osteoporosis in Postmenopausal Women BINOSTO effervescent tablet [0m[1;31m70[0m[31m mg is indicated for the treatment of osteoporosis in postmenopausal women. For the treatment of [0m
[31mosteoporosis, alendronate sodium increases bone mass and reduces the incidence of fractures, including those of the hip and spine [0m[1;31m([0m[31mvertebral compression fractures[0m[1;31m)[0m[31m. [0m[1;31m[[0m[31mSee Clinical Studies [0m[1;31m([0m[1;31m14.1[0m[1;31m)[0m[31m .[0m[1;31m][0m[31m [0m[1;31m1[0m[31m. [0m
[31mALENDRONATE: indications_and_usage: [0m[1;31m2[0m[31m Treatment to Increase Bone Mass in Men With Osteoporosis BINOSTO is indicated for treatment to increase bone mass in men with osteoporosis [0m[31m . [0m[1;31m1.3[0m[31m Important [0m
[31mLimitations of Use The optimal duration of use has not been determined. The safety and effectiveness of BINOSTO for the treatment of osteoporosis are based on clinical data of four years duration. All[0m
[31mpatients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after [0m[1;31m3[0m[31m [0m
[31mto [0m[1;31m5[0m[31m years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: warnings_and_cautions: There have been post-marketing reports of gastric and duodenal ulcers with oral bisphosphonate use, some severe and with complications, although no [0m
[31mincreased risk was observed in controlled clinical trials [0m[31m . [0m[1;31m5.2[0m[31m Mineral Metabolism Hypocalcemia must be corrected before initiating therapy with BINOSTO [0m[31m. Other disorders affecting mineral metabolism[0m
[1;31m([0m[31msuch as vitamin D deficiency[0m[1;31m)[0m[31m should also be effectively treated. In patients with these conditions, serum calcium and symptoms of hypocalcemia should be monitored during therapy with BINOSTO. [0m
[31mPresumably due to the effects of BINOSTO on increasing bone mineral, small, asymptomatic decreases in serum calcium and phosphate may occur. Patients should receive adequate calcium and vitamin D [0m
[31mintake. [0m[1;31m5[0m[31m. ALENDRONATE: warnings_and_cautions: [0m[1;31m3[0m[31m Musculoskeletal Pain In post-marketing experience, severe and occasionally incapacitating bone, joint, and/or muscle pain has been reported in patients[0m
[31mtaking bisphosphonates that are approved for the treatment of osteoporosis [0m[31m . This category of drugs includes BINOSTO. Most of the patients were postmenopausal women. The time to onset of symptoms [0m
[31mvaried from one day to several months after starting the drug. Discontinue use if severe symptoms develop. Most patients had relief of symptoms after stopping. A subset had recurrence of symptoms when[0m
[31mrechallenged with the same drug or another bisphosphonate. In placebo-controlled clinical studies of alendronate sodium, the percentages of patients with these symptoms were similar in the alendronate[0m
[31msodium and placebo groups. [0m[1;31m5[0m[31m. ALENDRONATE: warnings_and_cautions: [0m[1;31m4[0m[31m Osteonecrosis of the Jaw Osteonecrosis of the jaw [0m[1;31m([0m[31mONJ[0m[1;31m)[0m[31m, which can occur spontaneously, is generally associated with tooth [0m
[31mextraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates, including alendronate sodium. Known risk factors for osteonecrosis of the jaw include [0m
[31minvasive dental procedures [0m[1;31m([0m[31me.g., tooth extraction, dental implants, boney surgery[0m[1;31m)[0m[31m, diagnosis of cancer, concomitant therapies [0m[1;31m([0m[31me.g., chemotherapy, corticosteroids, angiogenesis inhibitors[0m[1;31m)[0m[31m, poor [0m
[31moral hygiene, and co-morbid disorders [0m[1;31m([0m[31me.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures[0m[1;31m)[0m[31m. The risk of ONJ may increase with duration of[0m
[31mexposure to bisphosphonates. For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ. ALENDRONATE: warnings_and_cautions: Clinical [0m
[31mjudgment of the treating physician and/or oral surgeon should guide the management plan of each patient based on individual benefit/risk assessment. Patients who develop osteonecrosis of the jaw while[0m
[31mon bisphosphonate therapy should receive care by an oral surgeon. In these patients, extensive dental surgery to treat ONJ may exacerbate the condition. Discontinuation of bisphosphonate therapy [0m
[31mshould be considered based on individual benefit/risk assessment. [0m[1;31m5.5[0m[31m Atypical Subtrochanteric and Diaphyseal Femoral Fractures Atypical, low-energy, or low trauma fractures of the femoral shaft have [0m
[31mbeen reported in bisphosphonate-treated patients. These fractures can occur anywhere in the femoral shaft from just below the lesser trochanter to above the supracondylar flare and are transverse or [0m
[31mshort oblique in orientation without evidence of comminution. ALENDRONATE: warnings_and_cautions: Causality has not been established as these fractures also occur in osteoporotic patients who have not[0m
[31mbeen treated with bisphosphonates. Atypical femur fractures most commonly occur with minimal or no trauma to the affected area. They may be bilateral and many patients report prodromal pain in the [0m
[31maffected area, usually presenting as dull, aching thigh pain, weeks to months before a complete fracture occurs. A number of reports note that patients were also receiving treatment with [0m
[31mglucocorticoids [0m[1;31m([0m[31me.g., prednisone[0m[1;31m)[0m[31m at the time of fracture. Any patient with a history of bisphosphonate exposure who presents with thigh or groin pain should be suspected of having an atypical [0m
[31mfracture and should be evaluated to rule out an incomplete femur fracture. Patients presenting with an atypical fracture should also be assessed for symptoms and signs of fracture in the contralateral[0m
[31mlimb.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: warnings_and_cautions: [0m[1;31m5[0m[31m WARNINGS AND PRECAUTIONS Upper Gastrointestinal Adverse Reactions can occur. Instruct patients to follow dosing instructions. Discontinue if new or [0m
[31mworsening symptoms occur. [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[31m Hypocalcemia can worsen and must be corrected prior to use. [0m[1;31m([0m[31m [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m Severe Bone, Joint, Muscle Pain may occur. Discontinue use if severe symptoms develop. [0m[1;31m([0m[31m [0m[1;31m5.3[0m[31m [0m[1;31m)[0m[31m [0m
[31mOsteonecrosis of the Jaw has been reported. [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[31m Atypical Femur Fractures have been reported. Patients with new thigh or groin pain should be evaluated to rule out a femoral fracture. [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[31m [0m
[31mSodium Content: Each tablet contains [0m[1;31m603[0m[31m mg sodium, equivalent to [0m[1;31m1532[0m[31m mg NaCl. Use caution in patients on sodium restriction. [0m[1;31m([0m[31m [0m[1;31m5.7[0m[31m [0m[1;31m)[0m[31m [0m[1;31m5[0m[31m. ALENDRONATE: warnings_and_cautions: [0m[1;31m1[0m[31m Upper Gastrointestinal [0m
[31mAdverse Reactions BINOSTO, like other bisphosphonates administered orally, may cause local irritation of the upper gastrointestinal mucosa. Because of these possible irritant effects and a potential [0m
[31mfor worsening of the underlying disease, caution should be used when BINOSTO is given to patients with active upper gastrointestinal problems [0m[1;31m([0m[31msuch as known Barrett's esophagus, dysphagia, other [0m
[31mesophageal diseases, gastritis, duodenitis, or ulcers[0m[1;31m)[0m[31m. Esophageal adverse experiences, such as esophagitis, esophageal ulcers and esophageal erosions, occasionally with bleeding and rarely followed [0m
[31mby esophageal stricture or perforation, have been reported in patients receiving treatment with oral bisphosphonates including alendronate sodium. In some cases these have been severe and required [0m
[31mhospitalization. ALENDRONATE: warnings_and_cautions: Physicians should therefore be alert to any signs or symptoms signaling a possible esophageal reaction and patients should be instructed to [0m
[31mdiscontinue BINOSTO and seek medical attention if they develop dysphagia, odynophagia, retrosternal pain or new or worsening heartburn. The risk of severe esophageal adverse experiences appears to be [0m
[31mgreater in patients who lie down after taking oral bisphosphonates including alendronate sodium, and/or who continue to take oral bisphosphonates including alendronate sodium after developing symptoms[0m
[31msuggestive of esophageal irritation. Therefore, it is very important that the full dosing instructions are provided to, and understood by, the patient [0m[31m . In patients who cannot comply with dosing [0m
[31minstructions due to mental disability, therapy with BINOSTO should be used under appropriate supervision.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: adverse_reactions_table: [0m[1;31m0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Dyspepsia<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.7[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.2[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Acid regurgitation<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.9[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> [0m
[31mNausea<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.9[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Abdominal distention<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Constipation<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.8[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.6[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> [0m
[31mFlatulence<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.6[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Gastritis<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.2[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1[0m[31m. ALENDRONATE: adverse_reactions_table: [0m[1;31m1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Gastric ulcer<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m
[31mcolspan[0m[31m=[0m[31m"3"[0m[31m>Musculoskeletal<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Musculoskeletal [0m[1;31m([0m[31mbone, muscle, joint[0m[1;31m)[0m[31m pain<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.9[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m3.2[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Muscle cramp<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.2[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1[0m[31m. ALENDRONATE: [0m
[31madverse_reactions_table: [0m[1;31m1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[1;31m>[0m[31m         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ALENDRONATE increase the risk of aplastic anemia?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ALENDRONATE increase the risk of aplastic anemia?[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE increase the risk of aplastic anemia?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE increase the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ALENDRONATE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does ALENDRONATE increase the risk of aplastic [0m
[31manemia?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ALENDRONATE increase the risk of aplastic anemia?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ALENDRONATE increase the risk of aplastic anemia?[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE increase the risk of aplastic anemia?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE increase the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ALENDRONATE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: ALENDRONATE: adverse_reactions: [0m[1;31m1[0m[31m [0m[1;31m1.8[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.2[0m[31m Diarrhea [0m[1;31m3.1[0m[31m [0m[1;31m1.8[0m[31m [0m[1;31m0.6[0m[31m [0m[1;31m0.3[0m[31m Flatulence [0m[1;31m2.6[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m0.2[0m[31m [0m[1;31m0.3[0m[31m Acid regurgitation [0m[1;31m2.0[0m[31m [0m[1;31m4.3[0m[31m [0m[1;31m1.1[0m[31m [0m[1;31m0.9[0m[31m Esophageal ulcer [0m[1;31m1.5[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.1[0m[31m [0m[1;31m0.1[0m[31m Vomiting [0m[1;31m1.0[0m[31m [0m[1;31m1.5[0m[31m [0m[1;31m0.2[0m[31m [0m[1;31m0.3[0m[31m [0m
[31mDysphagia [0m[1;31m1.0[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.1[0m[31m [0m[1;31m0.1[0m[31m Abdominal distention [0m[1;31m1.0[0m[31m [0m[1;31m0.8[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.0[0m[31m Gastritis [0m[1;31m0.5[0m[31m [0m[1;31m1.3[0m[31m [0m[1;31m0.6[0m[31m [0m[1;31m0.7[0m[31m Musculoskeletal Musculoskeletal [0m[1;31m([0m[31mbone, muscle or joint[0m[1;31m)[0m[31m pain [0m[1;31m4.1[0m[31m [0m[1;31m2.5[0m[31m [0m[1;31m0.4[0m[31m [0m[1;31m0[0m[31m. ALENDRONATE: adverse_reactions: [0m[1;31m3[0m[31m [0m
[31mMuscle cramp [0m[1;31m0.0[0m[31m [0m[1;31m1.0[0m[31m [0m[1;31m0.2[0m[31m [0m[1;31m0.1[0m[31m Nervous system/psychiatric Headache [0m[1;31m2.6[0m[31m [0m[1;31m1.5[0m[31m [0m[1;31m0.2[0m[31m [0m[1;31m0.2[0m[31m Dizziness [0m[1;31m0.0[0m[31m [0m[1;31m1.0[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.1[0m[31m Special senses Taste perversion [0m[1;31m0.5[0m[31m [0m[1;31m1.0[0m[31m [0m[1;31m0.1[0m[31m [0m[1;31m0.0[0m[31m Rarely, rash and erythema have occurred. [0m
[31mGastrointestinal Adverse Reactions: One patient treated with alendronate sodium [0m[1;31m([0m[1;31m10[0m[31m mg/day[0m[1;31m)[0m[31m, who had a history of peptic ulcer disease and gastrectomy and who was taking concomitant aspirin developed [0m
[31man anastomotic ulcer with mild hemorrhage, which was considered drug related. Aspirin and alendronate sodium were discontinued and the patient recovered. ALENDRONATE: adverse_reactions: In the Study [0m[1;31m1[0m
[31mand Study [0m[1;31m2[0m[31m populations, [0m[1;31m49[0m[31m-[0m[1;31m54[0m[31m% had a history of gastrointestinal disorders at baseline and [0m[1;31m54[0m[31m-[0m[1;31m89[0m[31m% used nonsteroidal anti-inflammatory drugs or aspirin at some time during the studies [0m[1;31m[[0m[31m see Warnings [0m
[31mand Precautions [0m[1;31m([0m[1;31m5.1[0m[1;31m)[0m[31m [0m[1;31m][0m[31m. Laboratory Test Findings: In double-blind, multicenter, controlled studies, asymptomatic, mild, and transient decreases in serum calcium and phosphate were observed in [0m
[31mapproximately [0m[1;31m18[0m[31m% and [0m[1;31m10[0m[31m%, respectively, of patients taking alendronate versus approximately [0m[1;31m12[0m[31m% and [0m[1;31m3[0m[31m% of those taking placebo. However, the incidences of decreases in serum calcium to less than [0m[1;31m8.0[0m[31m [0m
[31mmg/dL [0m[1;31m([0m[1;31m2.0[0m[31m mM[0m[1;31m)[0m[31m and serum phosphate to less than or equal to [0m[1;31m2.0[0m[31m mg/dL [0m[1;31m([0m[1;31m0.65[0m[31m mM[0m[1;31m)[0m[31m were similar in both treatment groups. ALENDRONATE: adverse_reactions: Weekly Dosing The safety of alendronate sodium [0m[1;31m70[0m
[31mmg once weekly for the treatment of postmenopausal osteoporosis was assessed in a one-year, double-blind, multicenter study comparing alendronate [0m[1;31m70[0m[31m mg once weekly and alendronate [0m[1;31m10[0m[31m mg daily. The [0m
[31moverall safety and tolerability profiles of once weekly alendronate [0m[1;31m70[0m[31m mg and alendronate [0m[1;31m10[0m[31m mg daily were similar. The adverse reactions considered by the investigators as possibly, probably, or [0m
[31mdefinitely drug related in greater than or equal to [0m[1;31m1[0m[31m% of patients in either treatment group are presented in Table [0m[1;31m2[0m[31m. ALENDRONATE: adverse_reactions: Table [0m[1;31m2[0m[31m Osteoporosis Treatment Studies in [0m
[31mPostmenopausal Women Adverse Reactions Considered Possibly, Probably, or Definitely Drug Related by the Investigators and Reported in Greater Than or Equal to [0m[1;31m1[0m[31m% of Patients Once Weekly Alendronate [0m
[31mSodium [0m[1;31m70[0m[31m mg % [0m[1;31m([0m[31mN = [0m[1;31m519[0m[1;31m)[0m[31m Once Daily Alendronate Sodium [0m[1;31m10[0m[31m mg % [0m[1;31m([0m[31mN = [0m[1;31m370[0m[1;31m)[0m[31m Gastrointestinal Abdominal pain [0m[1;31m3.7[0m[31m [0m[1;31m3.0[0m[31m Dyspepsia [0m[1;31m2.7[0m[31m [0m[1;31m2.2[0m[31m Acid regurgitation [0m[1;31m1.9[0m[31m [0m[1;31m2.4[0m[31m Nausea [0m[1;31m1.9[0m[31m [0m[1;31m2.4[0m[31m Abdominal distention [0m[1;31m1.0[0m[31m [0m
[1;31m1.4[0m[31m Constipation [0m[1;31m0.8[0m[31m [0m[1;31m1.6[0m[31m Flatulence [0m[1;31m0.4[0m[31m [0m[1;31m1.6[0m[31m Gastritis [0m[1;31m0.2[0m[31m [0m[1;31m1.1[0m[31m Gastric ulcer [0m[1;31m0.0[0m[31m [0m[1;31m1[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: adverse_reactions: [0m[1;31m0[0m[31m Abdominal pain [0m[1;31m2.1[0m[31m [0m[1;31m1.1[0m[31m [0m[1;31m0.9[0m[31m [0m[1;31m3.4[0m[31m Nausea [0m[1;31m2.1[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m6.2[0m[31m Post-Marketing Experience The following adverse reactions have been identified during post-approval[0m
[31muse of alendronate sodium. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal [0m
[31mrelationship to drug exposure. Body as a Whole : hypersensitivity reactions including urticaria and angioedema. Transient symptoms of myalgia, malaise, asthenia and fever have been reported with [0m
[31malendronate, typically in association with initiation of treatment. Symptomatic hypocalcemia has occurred, generally in association with predisposing conditions. Peripheral edema. ALENDRONATE: [0m
[31madverse_reactions: Gastrointestinal : esophagitis, esophageal erosions, esophageal ulcers, esophageal stricture or perforation, and oropharyngeal ulceration. Gastric or duodenal ulcers, some severe [0m
[31mand with complications have also been reported [0m[31m . Dental : Localized osteonecrosis of the jaw, generally associated with tooth extraction and/or local infection with delayed healing, has been reported[0m
[31m. Musculoskeletal : bone, joint, and/or muscle pain, occasionally severe and incapacitating [0m[31m ; joint swelling; low-energy femoral shaft and subtrochanteric fractures [0m[31m . Nervous system : dizziness and [0m
[31mvertigo. ALENDRONATE: adverse_reactions: Pulmonary: acute asthma exacerbations Skin : rash [0m[1;31m([0m[31moccasionally with photosensitivity[0m[1;31m)[0m[31m, pruritus, alopecia, severe skin reactions, including Stevens-Johnson [0m
[31msyndrome and toxic epidermal necrolysis. Special Senses : uveitis, scleritis or episcleritis. Cholesteatoma of the external auditory canal [0m[1;31m([0m[31mfocal osteonecrosis[0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: adverse_reactions_table: >[0m[1;31m10[0m[31m mg % [0m[1;31m([0m[31mN = [0m[1;31m146[0m[1;31m)[0m[1;31m<[0m[31m/[0m[31mth[0m[31m><th>Placebo % [0m[1;31m([0m[31mN = [0m[1;31m95[0m[1;31m)[0m[31m<[0m[31m/[0m[31mth[0m[31m><th>[0m[1;31m70[0m[31m mg % [0m[1;31m([0m[31mN = [0m[1;31m109[0m[1;31m)[0m[31m<[0m[31m/[0m[31mth[0m[31m><th>Placebo % [0m[1;31m([0m[31mN = [0m[1;31m58[0m[1;31m)[0m[31m<[0m[31m/[0m[31mth[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mthead[0m[31m><tbody><tr><td [0m
[31mcolspan[0m[31m=[0m[31m"5"[0m[31m>Gastrointestinal<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Acid regurgitation<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m4.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m3.2[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> [0m
[31mFlatulence<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m4.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Gastroesophageal reflux disease<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.7[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m3.2[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2[0m[31m. ALENDRONATE: adverse_reactions_table: [0m
[1;31m8[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Dyspepsia<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m3.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.8[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.7[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Diarrhea<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.8[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Abdominal [0m
[31mpain<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.9[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m3.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Nausea<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0[0m[31m. ALENDRONATE: adverse_reactions_table: [0m[1;31m0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[31m>         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: openfda: spl_set_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: contraindications: [0m[1;31m4[0m[31m CONTRAINDICATIONS BINOSTO is contraindicated in patients with the following conditions: Abnormalities of the esophagus which delay esophageal emptying such [0m
[31mas stricture or achalasia [0m[31m Inability to stand or sit upright for at least [0m[1;31m30[0m[31m minutes [0m[31m Do not administer BINOSTO to patients at increased risk of aspiration Hypocalcemia [0m[31m Hypersensitivity to any [0m
[31mcomponent of this product. Hypersensitivity reactions including urticaria and angioedema have been reported [0m[31m . Abnormalities of the esophagus which delay emptying such as stricture or achalasia [0m[1;31m([0m[31m [0m[1;31m4[0m[31m , [0m
[1;31m5[0m[31m. ALENDRONATE: contraindications: [0m[1;31m1[0m[31m [0m[1;31m)[0m[31m Inability to stand/sit upright for at least [0m[1;31m30[0m[31m minutes [0m[1;31m([0m[31m [0m[1;31m4[0m[31m , [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[31m Increased risk of aspiration. [0m[1;31m([0m[31m [0m[1;31m4[0m[31m [0m[1;31m)[0m[31m Hypocalcemia [0m[1;31m([0m[31m [0m[1;31m4[0m[31m , [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m Hypersensitivity to any component[0m
[31mof this product [0m[1;31m([0m[31m [0m[1;31m4[0m[31m , [0m[1;31m6[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: animal_pharmacology_and_or_toxicology: [0m[1;31m13.2[0m[31m Animal Toxicology and/or Pharmacology The relative inhibitory activities on bone resorption and mineralization of alendronate and [0m
[31metidronate were compared in the Schenk assay, which is based on histological examination of the epiphyses of growing rats. In this assay, the lowest dose of alendronate that interfered with bone [0m
[31mmineralization [0m[1;31m([0m[31mleading to osteomalacia[0m[1;31m)[0m[31m was [0m[1;31m6000[0m[31m-fold the antiresorptive dose. The corresponding ratio for etidronate was one to one. These data suggest that alendronate administered in therapeutic [0m
[31mdoses is highly unlikely to induce osteomalacia.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: nonclinical_toxicology: [0m[1;31m13[0m[31m NONCLINICAL TOXICOLOGY [0m[1;31m13.1[0m[31m Carcinogenesis, Mutagenesis, Impairment of Fertility Harderian gland [0m[1;31m([0m[31ma retro-orbital gland not present in humans[0m[1;31m)[0m[31m adenomas[0m
[31mwere increased in high-dose female mice [0m[1;31m([0m[31mp[0m[31m=[0m[1;31m0[0m[1;31m.003[0m[1;31m)[0m[31m in a [0m[1;31m92[0m[31m-week oral carcinogenicity study at doses of alendronate of [0m[1;31m1[0m[31m, [0m[1;31m3[0m[31m, and [0m[1;31m10[0m[31m mg/kg/day [0m[1;31m([0m[31mmales[0m[1;31m)[0m[31m or [0m[1;31m1[0m[31m, [0m[1;31m2[0m[31m, and [0m[1;31m5[0m[31m mg/kg/day [0m[1;31m([0m[31mfemales[0m[1;31m)[0m[31m. These doses are [0m
[31mequivalent to [0m[1;31m0.12[0m[31m to [0m[1;31m1.2[0m[31m times a maximum recommended daily dose of [0m[1;31m40[0m[31m mg, based on surface area, mg/m [0m[1;31m2[0m[31m . The relevance of this finding to humans is unknown. Parafollicular cell [0m[1;31m([0m[31mthyroid[0m[1;31m)[0m[31m adenomas [0m
[31mwere increased in high-dose male rats [0m[1;31m([0m[31mp[0m[31m=[0m[1;31m0[0m[31m. ALENDRONATE: nonclinical_toxicology: [0m[1;31m003[0m[1;31m)[0m[31m in a [0m[1;31m2[0m[31m-year oral carcinogenicity study at doses of [0m[1;31m1[0m[31m and [0m[1;31m3.75[0m[31m mg/kg body weight. These doses are equivalent to [0m
[1;31m0.26[0m[31m and [0m[1;31m1[0m[31m times a [0m[1;31m40[0m[31m mg human daily dose based on surface area, mg/m [0m[1;31m2[0m[31m . The relevance of this finding to humans is unknown. Alendronate sodium was not genotoxic in the in vitro microbial mutagenesis[0m
[31massay with and without metabolic activation, in an in vitro mammalian cell mutagenesis assay, in an in vitro alkaline elution assay in rat hepatocytes, and in an in vivo chromosomal aberration assay [0m
[31min mice. In an in vitro chromosomal aberration assay in Chinese hamster ovary cells, however, alendronate gave equivocal results. Alendronate sodium had no effect on fertility [0m[1;31m([0m[31mmale or female[0m[1;31m)[0m[31m in rats[0m
[31mat oral doses up to [0m[1;31m5[0m[31m mg/kg/day [0m[1;31m([0m[1;31m1[0m[31m. ALENDRONATE: nonclinical_toxicology: [0m[1;31m3[0m[31m times a [0m[1;31m40[0m[31m mg human daily dose based on surface area, mg/m [0m[1;31m2[0m[31m [0m[1;31m)[0m[31m. [0m[1;31m13.2[0m[31m Animal Toxicology and/or Pharmacology The relative [0m
[31minhibitory activities on bone resorption and mineralization of alendronate and etidronate were compared in the Schenk assay, which is based on histological examination of the epiphyses of growing [0m
[31mrats. In this assay, the lowest dose of alendronate that interfered with bone mineralization [0m[1;31m([0m[31mleading to osteomalacia[0m[1;31m)[0m[31m was [0m[1;31m6000[0m[31m-fold the antiresorptive dose. The corresponding ratio for etidronate was[0m
[31mone to one. These data suggest that alendronate administered in therapeutic doses is highly unlikely to induce osteomalacia.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: clinical_pharmacology: [0m[1;31m12[0m[31m CLINICAL PHARMACOLOGY [0m[1;31m12.1[0m[31m Mechanism of Action Animal studies have indicated the following mode of action. At the cellular level, alendronate shows [0m
[31mpreferential localization to sites of bone resorption, specifically under osteoclasts. The osteoclasts adhere normally to the bone surface but lack the ruffled border that is indicative of active [0m
[31mresorption. Alendronate does not interfere with osteoclast recruitment or attachment, but it does inhibit osteoclast activity. Studies in mice on the localization of radioactive [0m[1;31m[[0m[31m [0m[1;31m3[0m[31m H[0m[1;31m][0m[31malendronate in [0m
[31mbone showed about [0m[1;31m10[0m[31m-fold higher uptake on osteoclast surfaces than on osteoblast surfaces. Bones examined [0m[1;31m6[0m[31m and [0m[1;31m49[0m[31m days after [0m[1;31m[[0m[31m [0m[1;31m3[0m[31m H[0m[1;31m][0m[31malendronate administration in rats and mice, respectively, showed [0m
[31mthat normal bone was formed on top of the alendronate, which was incorporated inside the matrix. ALENDRONATE: clinical_pharmacology: While incorporated in bone matrix, alendronate is not [0m
[31mpharmacologically active. Thus, alendronate must be continuously administered to suppress osteoclasts on newly formed resorption surfaces. Histomorphometry in baboons and rats showed that alendronate [0m
[31mtreatment reduces bone turnover [0m[1;31m([0m[31mi.e., the number of sites at which bone is remodeled[0m[1;31m)[0m[31m. In addition, bone formation exceeds bone resorption at these remodeling sites, leading to progressive gains in [0m
[31mbone mass. [0m[1;31m12.2[0m[31m Pharmacodynamics Alendronate is a bisphosphonate that binds to bone hydroxyapatite and specifically inhibits the activity of osteoclasts, the bone-resorbing cells. Alendronate reduces [0m
[31mbone resorption with no direct effect on bone formation, although the latter process is ultimately reduced because bone resorption and formation are coupled during bone turnover. ALENDRONATE: [0m
[31mclinical_pharmacology: Osteoporosis in Postmenopausal Women Osteoporosis is characterized by low bone mass that leads to an increased risk of fracture. The diagnosis can be confirmed by the finding of[0m
[31mlow bone mass, evidence of fracture on x-ray, a history of osteoporotic fracture, or height loss or kyphosis, indicative of vertebral [0m[1;31m([0m[31mspinal[0m[1;31m)[0m[31m fracture. Osteoporosis occurs in both males and females [0m
[31mbut is most common among women following the menopause, when bone turnover increases and the rate of bone resorption exceeds that of bone formation. These changes result in progressive bone loss and [0m
[31mlead to osteoporosis in a significant proportion of women over age [0m[1;31m50[0m[31m. Fractures, usually of the spine, hip, and wrist, are the common consequences. From age [0m[1;31m50[0m[31m to age [0m[1;31m90[0m[31m, the risk of hip fracture in [0m
[31mwhite women increases [0m[1;31m50[0m[31m-fold and the risk of vertebral fracture [0m[1;31m15[0m[31m- to [0m[1;31m30[0m[31m-fold. ALENDRONATE: clinical_pharmacology: It is estimated that approximately [0m[1;31m40[0m[31m% of [0m[1;31m50[0m[31m-year-old women will sustain one or [0m
[31mmore osteoporosis-related fractures of the spine, hip, or wrist during their remaining lifetimes. Hip fractures, in particular, are associated with substantial morbidity, disability, and mortality. [0m
[31mDaily oral doses of alendronate sodium [0m[1;31m([0m[1;31m5[0m[31m, [0m[1;31m20[0m[31m, and [0m[1;31m40[0m[31m mg for six weeks[0m[1;31m)[0m[31m in postmenopausal women produced biochemical changes indicative of dose-dependent inhibition of bone resorption, including [0m
[31mdecreases in urinary calcium and urinary markers of bone collagen degradation [0m[1;31m([0m[31msuch as deoxypyridinoline and cross-linked N-telopeptides of type I collagen[0m[1;31m)[0m[31m. These biochemical changes tended to return[0m
[31mtoward baseline values as early as [0m[1;31m3[0m[31m weeks following the discontinuation of therapy with alendronate and did not differ from placebo after [0m[1;31m7[0m[31m months. ALENDRONATE: clinical_pharmacology: Long-term [0m
[31mtreatment of osteoporosis with alendronate sodium [0m[1;31m10[0m[31m mg/day [0m[1;31m([0m[31mfor up to five years[0m[1;31m)[0m[31m reduced urinary excretion of markers of bone resorption, deoxypyridinoline and cross-linked N-telopeptides of type l [0m
[31mcollagen, by approximately [0m[1;31m50[0m[31m% and [0m[1;31m70[0m[31m%, respectively, to reach levels similar to those seen in healthy premenopausal women. Similar decreases were seen in patients in osteoporosis prevention studies [0m
[31mwho received alendronate sodium [0m[1;31m5[0m[31m mg/day. The decrease in the rate of bone resorption indicated by these markers was evident as early as [0m[1;31m1[0m[31m month and at [0m[1;31m3[0m[31m to [0m[1;31m6[0m[31m months reached a plateau that was [0m
[31mmaintained for the entire duration of treatment with alendronate sodium.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: indications_and_usage: [0m[1;31m1[0m[31m INDICATIONS AND USAGE BINOSTO is a bisphosphonate indicated for: Treatment of osteoporosis in postmenopausal women [0m[1;31m([0m[31m [0m[1;31m1.1[0m[31m [0m[1;31m)[0m[31m Treatment to increase bone [0m
[31mmass in men with osteoporosis [0m[1;31m([0m[31m [0m[1;31m1.2[0m[31m [0m[1;31m)[0m[31m Limitation of use: Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after [0m[1;31m3[0m[31m to [0m[1;31m5[0m[31m years of use[0m
[1;31m([0m[31m [0m[1;31m1.3[0m[31m [0m[1;31m)[0m[31m [0m[1;31m1.1[0m[31m Treatment of Osteoporosis in Postmenopausal Women BINOSTO effervescent tablet [0m[1;31m70[0m[31m mg is indicated for the treatment of osteoporosis in postmenopausal women. For the treatment of [0m
[31mosteoporosis, alendronate sodium increases bone mass and reduces the incidence of fractures, including those of the hip and spine [0m[1;31m([0m[31mvertebral compression fractures[0m[1;31m)[0m[31m. [0m[1;31m[[0m[31mSee Clinical Studies [0m[1;31m([0m[1;31m14.1[0m[1;31m)[0m[31m .[0m[1;31m][0m[31m [0m[1;31m1[0m[31m. [0m
[31mALENDRONATE: indications_and_usage: [0m[1;31m2[0m[31m Treatment to Increase Bone Mass in Men With Osteoporosis BINOSTO is indicated for treatment to increase bone mass in men with osteoporosis [0m[31m . [0m[1;31m1.3[0m[31m Important [0m
[31mLimitations of Use The optimal duration of use has not been determined. The safety and effectiveness of BINOSTO for the treatment of osteoporosis are based on clinical data of four years duration. All[0m
[31mpatients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after [0m[1;31m3[0m[31m [0m
[31mto [0m[1;31m5[0m[31m years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: warnings_and_cautions: There have been post-marketing reports of gastric and duodenal ulcers with oral bisphosphonate use, some severe and with complications, although no [0m
[31mincreased risk was observed in controlled clinical trials [0m[31m . [0m[1;31m5.2[0m[31m Mineral Metabolism Hypocalcemia must be corrected before initiating therapy with BINOSTO [0m[31m. Other disorders affecting mineral metabolism[0m
[1;31m([0m[31msuch as vitamin D deficiency[0m[1;31m)[0m[31m should also be effectively treated. In patients with these conditions, serum calcium and symptoms of hypocalcemia should be monitored during therapy with BINOSTO. [0m
[31mPresumably due to the effects of BINOSTO on increasing bone mineral, small, asymptomatic decreases in serum calcium and phosphate may occur. Patients should receive adequate calcium and vitamin D [0m
[31mintake. [0m[1;31m5[0m[31m. ALENDRONATE: warnings_and_cautions: [0m[1;31m3[0m[31m Musculoskeletal Pain In post-marketing experience, severe and occasionally incapacitating bone, joint, and/or muscle pain has been reported in patients[0m
[31mtaking bisphosphonates that are approved for the treatment of osteoporosis [0m[31m . This category of drugs includes BINOSTO. Most of the patients were postmenopausal women. The time to onset of symptoms [0m
[31mvaried from one day to several months after starting the drug. Discontinue use if severe symptoms develop. Most patients had relief of symptoms after stopping. A subset had recurrence of symptoms when[0m
[31mrechallenged with the same drug or another bisphosphonate. In placebo-controlled clinical studies of alendronate sodium, the percentages of patients with these symptoms were similar in the alendronate[0m
[31msodium and placebo groups. [0m[1;31m5[0m[31m. ALENDRONATE: warnings_and_cautions: [0m[1;31m4[0m[31m Osteonecrosis of the Jaw Osteonecrosis of the jaw [0m[1;31m([0m[31mONJ[0m[1;31m)[0m[31m, which can occur spontaneously, is generally associated with tooth [0m
[31mextraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates, including alendronate sodium. Known risk factors for osteonecrosis of the jaw include [0m
[31minvasive dental procedures [0m[1;31m([0m[31me.g., tooth extraction, dental implants, boney surgery[0m[1;31m)[0m[31m, diagnosis of cancer, concomitant therapies [0m[1;31m([0m[31me.g., chemotherapy, corticosteroids, angiogenesis inhibitors[0m[1;31m)[0m[31m, poor [0m
[31moral hygiene, and co-morbid disorders [0m[1;31m([0m[31me.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures[0m[1;31m)[0m[31m. The risk of ONJ may increase with duration of[0m
[31mexposure to bisphosphonates. For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ. ALENDRONATE: warnings_and_cautions: Clinical [0m
[31mjudgment of the treating physician and/or oral surgeon should guide the management plan of each patient based on individual benefit/risk assessment. Patients who develop osteonecrosis of the jaw while[0m
[31mon bisphosphonate therapy should receive care by an oral surgeon. In these patients, extensive dental surgery to treat ONJ may exacerbate the condition. Discontinuation of bisphosphonate therapy [0m
[31mshould be considered based on individual benefit/risk assessment. [0m[1;31m5.5[0m[31m Atypical Subtrochanteric and Diaphyseal Femoral Fractures Atypical, low-energy, or low trauma fractures of the femoral shaft have [0m
[31mbeen reported in bisphosphonate-treated patients. These fractures can occur anywhere in the femoral shaft from just below the lesser trochanter to above the supracondylar flare and are transverse or [0m
[31mshort oblique in orientation without evidence of comminution. ALENDRONATE: warnings_and_cautions: Causality has not been established as these fractures also occur in osteoporotic patients who have not[0m
[31mbeen treated with bisphosphonates. Atypical femur fractures most commonly occur with minimal or no trauma to the affected area. They may be bilateral and many patients report prodromal pain in the [0m
[31maffected area, usually presenting as dull, aching thigh pain, weeks to months before a complete fracture occurs. A number of reports note that patients were also receiving treatment with [0m
[31mglucocorticoids [0m[1;31m([0m[31me.g., prednisone[0m[1;31m)[0m[31m at the time of fracture. Any patient with a history of bisphosphonate exposure who presents with thigh or groin pain should be suspected of having an atypical [0m
[31mfracture and should be evaluated to rule out an incomplete femur fracture. Patients presenting with an atypical fracture should also be assessed for symptoms and signs of fracture in the contralateral[0m
[31mlimb.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: warnings_and_cautions: [0m[1;31m5[0m[31m WARNINGS AND PRECAUTIONS Upper Gastrointestinal Adverse Reactions can occur. Instruct patients to follow dosing instructions. Discontinue if new or [0m
[31mworsening symptoms occur. [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[31m Hypocalcemia can worsen and must be corrected prior to use. [0m[1;31m([0m[31m [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m Severe Bone, Joint, Muscle Pain may occur. Discontinue use if severe symptoms develop. [0m[1;31m([0m[31m [0m[1;31m5.3[0m[31m [0m[1;31m)[0m[31m [0m
[31mOsteonecrosis of the Jaw has been reported. [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[31m Atypical Femur Fractures have been reported. Patients with new thigh or groin pain should be evaluated to rule out a femoral fracture. [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[31m [0m
[31mSodium Content: Each tablet contains [0m[1;31m603[0m[31m mg sodium, equivalent to [0m[1;31m1532[0m[31m mg NaCl. Use caution in patients on sodium restriction. [0m[1;31m([0m[31m [0m[1;31m5.7[0m[31m [0m[1;31m)[0m[31m [0m[1;31m5[0m[31m. ALENDRONATE: warnings_and_cautions: [0m[1;31m1[0m[31m Upper Gastrointestinal [0m
[31mAdverse Reactions BINOSTO, like other bisphosphonates administered orally, may cause local irritation of the upper gastrointestinal mucosa. Because of these possible irritant effects and a potential [0m
[31mfor worsening of the underlying disease, caution should be used when BINOSTO is given to patients with active upper gastrointestinal problems [0m[1;31m([0m[31msuch as known Barrett's esophagus, dysphagia, other [0m
[31mesophageal diseases, gastritis, duodenitis, or ulcers[0m[1;31m)[0m[31m. Esophageal adverse experiences, such as esophagitis, esophageal ulcers and esophageal erosions, occasionally with bleeding and rarely followed [0m
[31mby esophageal stricture or perforation, have been reported in patients receiving treatment with oral bisphosphonates including alendronate sodium. In some cases these have been severe and required [0m
[31mhospitalization. ALENDRONATE: warnings_and_cautions: Physicians should therefore be alert to any signs or symptoms signaling a possible esophageal reaction and patients should be instructed to [0m
[31mdiscontinue BINOSTO and seek medical attention if they develop dysphagia, odynophagia, retrosternal pain or new or worsening heartburn. The risk of severe esophageal adverse experiences appears to be [0m
[31mgreater in patients who lie down after taking oral bisphosphonates including alendronate sodium, and/or who continue to take oral bisphosphonates including alendronate sodium after developing symptoms[0m
[31msuggestive of esophageal irritation. Therefore, it is very important that the full dosing instructions are provided to, and understood by, the patient [0m[31m . In patients who cannot comply with dosing [0m
[31minstructions due to mental disability, therapy with BINOSTO should be used under appropriate supervision.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: adverse_reactions_table: [0m[1;31m0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Dyspepsia<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.7[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.2[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Acid regurgitation<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.9[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> [0m
[31mNausea<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.9[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Abdominal distention<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Constipation<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.8[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.6[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> [0m
[31mFlatulence<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.4[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.6[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Gastritis<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.2[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1[0m[31m. ALENDRONATE: adverse_reactions_table: [0m[1;31m1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Gastric ulcer<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.0[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1.1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m
[31mcolspan[0m[31m=[0m[31m"3"[0m[31m>Musculoskeletal<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Musculoskeletal [0m[1;31m([0m[31mbone, muscle, joint[0m[1;31m)[0m[31m pain<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m2.9[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m3.2[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Muscle cramp<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m0.2[0m[31m<[0m[31m/[0m[31mtd[0m[31m><td>[0m[1;31m1[0m[31m. ALENDRONATE: [0m
[31madverse_reactions_table: [0m[1;31m1[0m[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[1;31m>[0m[31m         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ALENDRONATE increase the risk of aplastic anemia?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ALENDRONATE increase the risk of aplastic anemia?[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE increase the risk of aplastic anemia?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE increase the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ALENDRONATE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does ALENDRONATE increase the risk of aplastic [0m
[31manemia?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does ALENDRONATE increase or decrease the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether ALENDRONATE increases the risk of aplastic anemia."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded with DO-NOT-KNOW, indicating that the FDA label for ALENDRONATE does not contain information regarding an increased risk of aplastic anemia."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does ALENDRONATE increase or decrease the risk of aplastic anemia?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether ALENDRONATE increases the risk of aplastic anemia."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded with DO-NOT-KNOW, indicating that the FDA label for ALENDRONATE does not contain information regarding an increased risk of aplastic anemia."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does ALENDRONATE increase or decrease the risk of aplastic anemia?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether ALENDRONATE increases the risk of aplastic anemia.[0m
[1;31m2[0m[31m. FDAHandler responded with DO-NOT-KNOW, indicating that the FDA label for ALENDRONATE does not contain information regarding an increased risk of aplastic anemia.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe FDA label for ALENDRONATE does not contain information regarding an increased risk of aplastic anemia, hence there is no known association between ALENDRONATE and aplastic anemia based on the FDA [0m
[32mlabel data.[0m
